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Abstract 
Development of new biodegradable implants and devices is necessary to meet the 
increasing needs of regenerative orthopaedic procedures. An important consideration 
while formulating new implant materials is that they should physico-chemically and 
biologically mimic bone-like properties. In this thesis, I have characterised four new 
Magnesium-Zirconia (Mg-Zr)-based biodegradable alloys, containing different quantities 
of Strontium (Sr) or Calcium (Ca). The mechanical and physico-chemical 
characterisation of these alloys was completed using X-ray diffraction (XRD), 
optical/electron microscopy, compression test and surface energy measurements, 
respectively and the corrosion behaviour was established by their hydrogen production 
rate in simulated body fluid (SBF). The alloys were grouped into two categories: bare 
alloys without surface modification and coated alloys with Collagen Type-I (Col-I) 
coating. Col-I extracted from rat-tail, and characterised using Fourier Transform Infra-
Red (FT-IR) spectroscopy, was used for dip-coating the Mg-based alloys. Both types of 
alloys were implanted into cavities made in the femur bones of male New Zealand White 
rabbits; cavities with no implant and observed for the same periods were kept as controls. 
The bone induction, osseointegration and implant stabilisation was assessed by 
histological, immunohistochemical and radiological methods. In vivo bone formation and 
mineral deposition around the implants was quantified by measuring the Bone Mineral 
Content/Density (BMC/BMD) using Dual-Energy X-Ray Absorptiometry (DXA). 
MC3T3-E1 osteoblasts were used to evaluate the in vitro cytocompatibility of both the 
bare and Col-I coated alloys. Quantitative RT-PCR was done to analyse the induction of 
bone marker genes in MC3T3-E1 cells by the alloys.  
Our results showed that Mg-Zr alloys containing appropriate quantities of Sr (2wt%) 
were more efficient in inducing implant osseointegration than other alloys. The Col-I 
Abstract 
 
xiii 
 
coated Mg-Zr-Sr alloy implants demonstrated increased mineral deposition on the peri-
implant surface in shorter periods of implantation with a dramatic decrease of osteoclast 
activity, as compared to the uncoated alloys, indicating the role of Col-I and Sr ion 
concentration in bone resorption and remodelling. The Col-I coated Mg-Zr-Ca alloys 
showed a tendency to form superior trabecular bone structure with better osteoinduction 
around the implants compared to the control and uncoated ones, indicating the role of Ca 
and Col-I coating in osseointegration and secondary stabilisation through the 
phenomenon of contact osteogenesis.  
These experiments provide strong evidence that implants made with Col-I coated Mg-Zr 
alloys could induce early onset of bone remodelling in the implant area, which results in 
superior osseointegration and quality of bone mineralisation as compared with uncoated 
Mg-Zr alloys. These results are discussed in the context of the physicochemical and 
biological properties of the alloys, which could be useful in determining the constitution 
of future generations of biodegradable orthopaedic implants. The Col-I coating induced 
early and enhanced bone remodelling could also reduce the risk of infections during the 
early stages of bone healing and wound recovery. 
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Chapter 1 
Introduction 
 
Magnesium (Mg) alloys are being studied as suitable orthopaedic biodegradable implants 
owing to their degradability and resemblance to human bone. Mg is the eighth most abundant 
element and is present in the Earth’s crust in about 2% [1]. It is the third most plentiful 
element dissolved in a concentration of about 0.13% in seawater and its compounds are 
produced from seawater, well and lake brines and bitterns, as well as from various minerals 
like dolomite, carnallite, magnesite and brucite [1]. 
Mg is naturally present in biological systems as Mg2+ ions and has a stimulatory role in bone 
formation [2-5]. Because of its low weight and natural biocompatibility, it has been suggested 
as a good implant material. In addition, Mg has some chemical properties that make it a very 
close mimic to natural bone. It has a density of 1.74 g/cm3, its elastic modulus is about 45 
GPa and it has a compressive strength close to that of the cortical bone [6-10]. Most 
importantly, due to their biodegradable property, Mg alloy implants are converted to a 
soluble, non-toxic oxide that is safely excreted in the urine [10, 11]. Hence, a second surgery 
for the removal of Mg implant is not required. 
Despite all the above advantageous properties, Mg has certain constraints as a bio-implant. 
Upon implantation, Mg alloy degrades very rapidly in vivo due to its low corrosion 
resistance. The degradation takes place according to the following reaction: 
Mg + 2H2O→ Mg(OH)2 + H2↑ 
This leads to the production of a large volume of hydrogen gas and results in a loss of 
mechanical integrity even before the tissue has sufficiently healed and new bone tissue has 
adequately regenerated [12-16]. Hydrogen gas production leads to increased alkalinity and 
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creates health risks for the patients [17]. This becomes the most challenging disadvantage of 
using pure Mg as bio-implants. Its poor mechanical strength and elastic modulus also do not 
meet the requirements of the patients to sustain the rigors of daily activity [6, 8, 14, 16]. 
Alloying Mg with other metals can enhance its performance because of the improved 
corrosion resistance and mechanical properties. Thirdly, the biocompatibility of existing Mg 
alloys is inadequate for biomedical applications because traditionally, they have been used 
for non-biological applications, including pyrotechnic and metallurgical, chemical, 
electrochemical, and structural [18]. Enhancement of the biocompatibility of Mg-based alloys 
is therefore a major challenge, and achieving optimal level of biocompatibility has become a 
critical criterion for selecting any biodegradable implant material. 
 
1.1 Hypothesis 
 
Although alloying of Mg can increase the corrosion resistance of these alloys to some extent, 
it cannot significantly improve the bone response upon implantation. The surrounding tissue 
interacts only with the surface of the implant. Osseointegration depends on the bio-
mineralisation of the implant into the surrounding tissue. As this interaction between the 
implant and the cells/tissues at the tissue–implant interface is a surface phenomenon, surface 
properties play a major role in determining both the biological response to implants and the 
material response to the physiological condition. Therefore, modification of the alloy surface 
is necessary to form a hard and yet biodegradable, biocompatible and corrosion resistant 
layer, while still preserving the bulk properties of the alloy. With this background, this thesis 
hypothesises the following: 
1. Zr is a biocompatible metal and has excellent positive impacts on the mechanical and 
corrosion properties of Mg alloys, when it is used at ≤ 5wt%.   
2. Sr has a positive impact on both the mechanical and biological properties of Mg-Zr-Sr 
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alloys and its concentration also should be ≤5wt%.  
3. The surface topography of Mg-Zr-Sr alloy samples is compatible as in vivo implants and 
these materials can generate new bone when used as bio-implants.  
4. Surface coating of Mg-Zr based alloys with Collagen Type-I (Col-I) will enhance the in 
vivo biocompatibility and new bone forming ability of these alloys. 
 
1.2 Thesis Objectives 
 
The objective of this thesis was to evaluate the in vivo biocompatibility, osteogenicity and 
mineral deposition by four Mg-Zr based alloys namely: Mg-5Zr, Mg-Zr-2Sr, Mg-2Zr-5Sr and 
Mg-5Zr-Ca. These objectives were achieved by investigation of the following aspects of the 
alloy implants: 
x Demonstrating the role of alloying elements - Zirconia (Zr), Calcium (Ca) and 
Strontium (Sr) in Mg-based alloys in modulating osseointegration, by looking into the 
physico-chemical properties of these alloys. 
x Surface modification of Mg-Zr-Ca alloys by Col-I coating and looking into its matrix 
mineralisation and secondary stabilisation. 
x Evaluation of the effect of two different concentrations of Sr on bone growth and 
mineral deposition, and the bone resorption capacity of Mg-Zr based alloys, by Col-I 
coating.  
 
1.3 Thesis Outline 
 
Chapter two discusses the literature review concerning the thesis, with emphasis on bone 
biology and types of bone cells and bone matrix. Also discussed is the role of biomaterials in 
orthopaedics with emphasis on biodegradable Mg-based alloys. The various surface 
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modification techniques developed to date, to improve the material performance as implants 
and for enhancing their bioactivity, are also discussed in detail.  
 
Chapter three lists the materials and methodology used in the experiments. However, 
methods specific to each chapter are discussed in detail in the individual chapters.  
 
Chapter four investigates the constituents and the role of individual alloying elements in 
controlling the in vivo implant osseointegration. The effect of mechanical and physico-
chemical properties on the in vivo peri-implant cellularity and bone formation has been 
discussed in this chapter, with highlights on proximity and the extent of bone formation by 
individual implants.  
 
Chapter five examines the necessity and importance of surface modification by Col-I coating 
to Mg-Zr-Ca alloys and discusses the influence of coating on implant secondary stabilisation. 
The matrix mineralisation and bone remodelling has been discussed in the context of Col-I 
coating.  
 
Chapter six describes the role of Sr-wt% and Col-I coating on the quality of new bone 
formation by looking into the qualitative trabecular bone mineralisation and bone resorption. 
Also discussed in this chapter is the significance of Sr concentration in the in vitro gene 
expression of bone formation markers. 
 
Chapter seven discusses the summary of the findings and highlights from this study and the 
work required to connect the gaps between the results.  
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Chapter eight provides the conclusion of the thesis and discusses the directions for future 
research.  
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Chapter 2 
Literature Review 
 
2.1 Introduction 
 
Orthopaedic implants, including modern dental implants, have achieved encouraging and 
successful results in the field of health care. The available orthopaedic materials have helped 
to restore structural integrity and functions in many cases including bone fractures [12] and 
total joint replacement [19], thereby improving quality of life. However, before efficient 
substitution of damaged bone tissue is achieved, it is important to understand the intricacies 
involved in the organisation of bone tissue as a whole, as the microenvironment of the 
scaffolds play an important role in stimulating tissue regeneration. This review summarises 
the architecture of bone tissue with a major focus on different cell types present in the bone 
and their functions. The orthopaedic biomaterials and materials related to Mg and its alloys, 
developed till date as implant materials for bone tissue engineering applications are 
discussed. The surface properties and surface modifications of these materials and their 
physico-chemical properties in relation to their responses to the cell biological processes are 
highlighted.  
 
2.2 Bone Structure and Morphology 
Bone consists of two types of osseous tissue namely the compact (cortical) bone and the 
spongy (trabecular) bone. Compact/cortical bone is very dense and solid and is found on the 
surface of the bone, whereas spongy/trabecular bone is relatively porous and is found in the 
interior of bone. The relative amounts of compact and spongy bone are related to function. 
The compact and trabecular bone are part of the long bones.  
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The surfaces of bones are wrapped with connective tissue called the periosteum, consisting of 
a fibrous outer layer and a cellular inner layer. It functions to separate the bone from the 
surrounding tissues and to provide a pathway for circulatory and nervous supply, along with 
assistance in bone growth and repair. It is also essential in forming joints because of its 
adjacent placement to tendons and ligaments. Beneath the periosteum lies endosteum, that 
lines the marrow cavity, the trabeculae of the spongy bone, and the inner surfaces of the 
central canals. A representative figure of a long bone, the humerus, is given in Fig 2.1.  
 
 
The long bone consists of a shaft, the diaphysis, and swollen ends on both sides, the 
epiphysis, in between two metaphysic regions. A cavity-like nutrient foramen allows nerve 
fibres and blood vessels to enter the diaphysis. Inside the diaphysis is a space called the 
medullary (or marrow) cavity that contains bone marrow. The process of bone remodelling 
occurs in this region, between the outer periosteum and an inner endosteal layer. The cortical 
Figure 2.1 The structure of long bones 
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bone contains a series of numerous concentric circular osteons, surrounded by interstitial 
lamellae, which in turn are connected by haversian canals that house the blood capillaries, 
veins and nerves of the bone tissue.  
 
2.3 Bone Composition 
Almost all the bone mass is made up of matrix. Approximately 65% of bone is composed of 
inorganic component and mineral (primarily carbonated hydroxyapatite) that provides 
strength and resistance to compression. The organic component of bone, mostly type-I 
Collagen, contributes about 20-25% to its composition (Fig 2.2). The remaining almost 10% 
is made up of water which remains bound to the collagen-mineral composite. The organic 
component of the bone mass is called the osteoid. Collagen fibres of type-I are the major 
component of the osteoid, around 90% of the organic portion, with smaller amounts of type 
III and V that are also found in the surrounding zone of the bone cells. The remaining 10% of 
the organic component makes up the non-collagenous proteins (NCPs), which play important 
roles in regulating collagen formation, cell attachment and mineralisation. Of this small 
amount of NCPs, almost 85% constitutes the extracellular proteins and the remainder is the 
cellular proteins of the bone cells. 
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2.4 Biology of Bone Cells  
The bone mass of a living individual is maintained by the coordinated activities of bone cells. 
The major types of cells that make up the bone can be typically divided into three types, 
namely osteoclasts, ostoblasts and osteocytes. 
 
2.4.1 Osteoclasts 
 
Osteoclasts are the cells responsible for bone resorption by their ability to dissolve mineral 
and degrading organic bone matrix in collagen fibres. Osteoclasts are derived from 
hematopoietic stem cells, or hematopoietic monocyte-macrophage lineage [20], and so the 
earliest precursor of the osteoclasts is found within the granulocyte-macrophage colony-
stimulating unit (CFU-GM) in bone marrow. These mononuclear precursors fuse to form the 
mature multinucleated osteoclasts and differentiate through the same pathway as that of 
macrophages and dendritic cells. Hence, a pro-myeloid precursor can differentiate into: 
Figure 2.2. Composition of bone matrix. The non-collagenous proteins (NCPs) of the organic 
matrix contribute to cell adhesion and mineralisation with the cellular and extracellular 
proteins. 
Chapter 2.Literature Review 
 
10 
 
osteoclasts, when exposed to receptor activator of NF-kB ligand [RANKL/tumor necrosis 
factor related activation induced cytokine (TRANCE), osteoprotegerin ligand (OPGL) or 
osteoclast differentiation factor (ODF)], a macrophage when exposed to macrophage colony-
stimulating factor (M-CSF), or a dendritic cell when exposed to granulocyte-macrophage 
colony-stimulating factor (GM-CSF) [21-24].  
The bone resorption by osteoclasts involves the following stepwise cellular activities: 
1. Migration to the resorption site and its attachment to the bone 
2. Polarisation and formation of new membrane domains 
3. Dissolution of hydroxyapatite 
4. Degradation of organic matrix 
5. Removal of degradation products from the resorption cavity/lacuna 
6. Apoptosis of the osteoclasts or their return to the non-resorbing state 
Figure 2.3. The generation, maturation and death of osteoclasts. Osteoclast precursors 
proliferate in response to cell specific receptor-activated molecules and growth factors and 
form committed osteoclast precursors which then differentiate to form multinucleated 
osteoclasts. Multinucleation is a key morphological feature of osteoclasts that distinguishes 
mature osteoclasts from immature cells. 
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After migration of the osteoclast to the resorption site, the resorbing osteoclasts become 
highly polarised cells and secrete numerous specialised membrane domains including the 
sealing zone, a ruffled border, a functional secretory domain and a basolateral membrane (Fig 
2.4). The process of bone resorption occurs in resorption bays called Howship’s lacuna. The 
osteoclasts attach to the bone membrane through the sealing zone and form a resorbing 
organelle by fusion of intracellular acidic vesicles with the ruffled border, the region of 
plasma membrane facing the bone [25, 26].  
 
Figure 2.4. Representative image of morphology of a bone-resorbing osteoclast. FSD- 
functional secretory domain, SZ- sealing zone. Mature osteoclasts become polarised with the 
apical domain towards the bone surface. Bone dissolution occurs through the action of matrix 
metalloproteases (MMPs), Cathepsin K (Cat K) and Tartrate-Resistant Acid Phosphatase 
(TRAP). The degradation debris are internalised into the cell and degraded by the lysosomes 
or via transcytosis. 
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During resorption, the plasma membrane attaches tightly to the bone matrix and seals the 
resorption site from its surroundings. The osteoclasts then resorb the mineralised bone matrix 
by dissolution of crystalline hydroxyapatite and proteolytic cleavage of the collagen-rich 
organic matrix. The tightly packed hydroxyapatite crystals are dissolved by targeted secretion 
of HCl through the ruffled border into the resorption lacuna [25, 26]. The proteolytic 
enzymes- lysosomal cysteine proteinases, matrix metalloproteinases (MMPs) (MMP-9 - 
gelatinase B/Collagenase Type-IV) and cathepsin K play significant roles in the resorption 
process [27-29]. After it has fulfilled its resorption task, the osteoclast undergoes fission into 
mononuclear cells or it dies by apoptosis.  
 
2.4.2 Osteoblasts 
 
Osteoblasts are the bone forming cells that originate from mesenchymal progenitor cells. The 
functions of osteoblasts include bone matrix protein secretion and bone mineralisation. After 
completion of bone matrix formation, some mature osteoblasts remain entrapped in the bone 
matrix and become osteocytes, some flatten to cover the quiescent bone surface as bone 
lining cells and the rest of them die by apoptosis (Fig 2.5).  
Figure 2.5. The phenomenon of osteoblastogenesis describing the osteoblast generation, 
maturation and death. Mature osteoblasts are surrounded by the bone matrix and are 
transformed into osteocytes, or are flattened to cover the quiescent bone surface as lining 
cells, or undergo cell death by apoptosis. 
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Osteoblast cells are cuboidal with a diameter of 15-30 μm. They contain a large nuclei 
located close to the basal membrane of the cell, an enlarged Golgi apparatus on the apical 
surface of the nuclei and extensive endoplasmic reticulum. They aid in bone formation by 
generating, depositing and mineralising bone matrix. They are present in the periostium 
region of the bone; however, a major reservoir of osteoblast and osteoprogenitor cells is the 
endosteum surface of the bone [30]. Osteoblasts express high levels of alkaline phosphatase 
(ALP) and osteocalcin, and the circulating concentrations of these proteins reflect the rate of 
bone formation. Osteoblasts also secrete type-I Collagen abundantly along with other 
specialised matrix proteins to form osteoid, the organic phase of bone that serves as a 
template for subsequent deposition of mineral in the form of hydroxyapatite. The osteoblasts 
deposit the extracellular matrix beneath the periosteum, entrapping the blood vessels by the 
formation of ridges and grooves, which eventually fuse together with the deposited matrix 
Figure 2.6. An overview of the organization of bone cells at the periosteum and the 
endosteum, and the formation of osteoid by the osteoblasts. 
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thereby, forming the osteon (Fig 2.6) [31]. 
The proliferating osteoblast progenitors express transcription factors of the helix-loop-helix 
family (eg, DNA-binding protein inhibitor ID) and the osteoprogenitor population is 
maintained by inhibiting the expression of genes that characterise the mature osteoblast 
phenotype. Two major proteins essential for establishing the osteoblast phenotypes are 
RUNX2 and transcription factor Sp7 or Osterix and the two major signalling pathways that 
promote osteoblast differentiation are those activated by BMPs and Wnts.  
Wnt proteins play key roles in the development and homeostasis of bone through their 
involvement in cell differentiation, proliferation and apoptosis. They stimulate the 
differentiation of preosteoblasts and the undifferentiated mesenchymal cells toward the 
osteoblastic lineage. The population of osteoblasts can increase either by an increase in their 
rate of production from progenitors, a decrease in the rate of their death by apoptosis, or a 
combination of the two. After completing bone matrix synthesis, some osteoblasts become 
flattened and cover the inactive bone surface as bone-lining cells.  
 
2.4.3 Osteocytes 
 
Osteocytes are formed from osteoblasts that become embedded in the bone matrix during the 
process of bone mineralisation. Osteocytes are the most abundant cells in bone comprising 
more than 90% of cells in the bone matrix. Mature osteocytes are stellate shaped enclosed 
within the lacuno-canalicular network of bone. They radiate slender cytoplasmic processes in 
all directions called canaliculi. These radiating canaliculae act as means of communication 
between the neighbouring osteocytes and the bone surface through gap junctions. It is 
through these connections that osteocytes facilitate the access of oxygen and nutrients (Fig 
2.7). 
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Osteogenic cells arise from mesenchymal stem cells (Fig 2.5). The mechanism of osteocyte 
formation and differentiation from osteoblasts is however unknown. Stimulation of 
osteoblasts to extend cytoplasmic projections and to make contact with embedded cells may 
result in their differentiation into osteocytes [32]. Hence, the stimuli that alter osteoblast fate 
would also affect osteocyte formation. Nevertheless, osteocytes are responsible for the 
biomechanical regulation of bone mass and structure through the formation of the bone 
remodelling compartment (BRC) (Fig 2.8) [33], as osteocytes detect fatigue-induced 
replacement of damaged bone through remodelling. The osteocytes sense the need for bone 
resorption and send signals to lining cells, which retract from the bone surface to form a 
BRC. Osteocytes in turn release molecules, including sclerostin and Dkk-1, which induces 
osteoblasts to differentiate and become functional. Osteocytes also respond to changes in 
mechanical load by inducing local changes in bone mass through modelling. Furthermore, 
osteocytes detect changes in the circulating hormonal levels and respond to it by altering the 
rate of bone formation and resorption. 
 
 
Figure 2.7. Schematic representation of osteocyte differentiation from osteoblasts. The matrix-
producing osteoblasts either become an osteocyte, a lining cell, or undergo apoptosis. 
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Osteocytes produce high levels of sclerostin that can be detected in the canaliculi. Sclerostin 
acts as an antagonist to the BMP family of proteins and the Wnt signalling pathway. Wnt are 
essential for osteoblastogenesis and provide the stimulus for differentiation of mesenchymal 
progenitors to the osteoblast lineage, along with regulation of osteoblast activity. Osteocytes 
regulate the function of osteoblasts and osteoclasts. In response to mechanical and hormonal 
signals, osteocytes secrete factors (such as osteoprotegerin OPG, RANKL, and sclerostin) 
that affect other bone cells by paracrine or autocrine mechanisms, and hormones that affect 
other tissues by endocrine mechanisms.  
The life span of osteocytes is determined by bone turnover, in which the osteoclasts resorb 
bone and destroy osteocytes [34] along with the bone itself. Osteocytes may live for decades 
if the particular bone in which they reside has a slow turnover rate. Osteocytes die by 
apoptosis similar to osteoblasts and osteoclasts and decreased osteocyte viability indicates 
Figure 2.8. Model depicting the bone remodelling compartment (BRC). Osteoclast precursors 
are transported to the BRC by marrow capillaries where they differentiate to mature 
osteoblasts under the effect of differentiating factors such as RANKL and OPG, which are 
derived from pre-existing osteocytes and initiate bone remodelling. 
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bone fragility. The rest are re-embedded during the process of new bone formation which in 
turn is resorbed later by osteoclasts. The level of apoptotic osteocytes is higher in unloaded 
bones and in bones exposed to high levels of mechanical strain [35]. In either case, increased 
apoptosis in osteocytes can be seen before any osteoclast resorption, and the apoptotic 
osteocytes accumulate in areas that are subsequently removed by osteoclasts.  
 
2.5 Biomaterials and Biocompatibility- General Concepts 
 
A biomaterial or a bioactive material refers to any non-living material that is designed to 
mimic a specific pre-existing micro niche and can interact, when integrated, with the 
biological system of the animal/human body. Biomaterials can induce the host cells to 
differentiate and regenerate to the desired tissue according to physiological pathways. Hence, 
a material that is inserted into a host tissue and is destined to induce a desired cellular 
behaviour belongs to a biomaterial family.  
Based on the material-host tissue reaction, biological materials are classified into three 
distinct categories: 
1. Biotolerant materials are separated from bone tissue by a layer of fibrous tissue. 
2. Bioactive materials have the property of establishing chemical bonds with bone tissue, 
known as osseointegration. 
3. Bioinert materials have the possibility of direct contact with the adjacent bone tissue. 
However, there is no chemical reaction between the implant and the tissue.  
Examples of some of the accepted biomaterials are given below: 
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Types of biomaterials Materials used 
Metals Stainless steel, Ti-based alloys, Co-Cr based alloys, Au alloys, 
Ag products, platinum electrodes  
Ceramics Alumina, zirconia, bioactive glasses, hydroxyapetite, calcium 
phosphates, porcelains, carbons 
Polymers Polyethylenes, polypropelenes, polyamides, polyesters, 
polyurethanes, poly (methyl-methacrylate) (PMMA), 
hydrogels  
Composites Bisphenol-A-Glycidyl-Methacrylate (Bis-GMA)-quartz/silica 
fillers, PMMA-glass fillers 
Natural biomaterials Silk fibroins, collagen, coral, chitins, keratin, cellulose 
 
Table 2.1. Commonly used biomaterials for implant applications 
  
The recognition of specific types of interface between a biomaterial and the host tissue 
brought the concept of biocompatibility. Also known as tissue compatibility, according to 
David F. Williams, biocompatibility refers to the ability of the substrate to support cellular 
activity, including the facilitation of molecular and mechanical signalling systems, in order to 
optimise tissue regeneration, without eliciting undesirable local or systemic responses in the 
eventual host” [36]. Hence, biocompatibility is the degree of reaction caused by a foreign 
material in the body. The biocompatibility of the material with the host tissue is a mutual 
interaction eliciting a response from both the material and the host tissue. These changes in 
the material and biological tissue may further lead to several other changes.  
 
2.6 Desired Properties of Biomaterials 
 
x The most important property of a biomaterial is that it should have a biocompatible 
chemical composition so as not to elicit an adverse tissue reaction when used for its 
purpose.  
x It should have a very good resistance to degradation and corrosion. 
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x It should have enough strength to sustain the mechanical load of the host joint during 
and after the surgery. 
x A low modulus (elasticity) to minimise bone resorption.  
x A high wear resistance to minimise wear and tear during weight loading. 
x Apart from the above clinical requirements, the manufacturing and economic 
requirements of materials should also be considered. Manufacturing requirements 
prioritise the materials to have properties that permit its fabrication in the optimum 
design configuration. Although the economic requirements are not a critical issue in 
human applications, cost effective development of materials must be considered for 
veterinary applications.  
 
2.7 Applications of Biomaterials 
 
x Oral/dental applications: Replacement of tooth and supporting gum tissues due to 
cavities and diseases can be done by a variety of materials. Metallic biomaterials like 
Ti and Co-Cr based metals have been recently used for tooth anchorage applications 
[37, 38]. Other tooth implants consist of ceramics including alumina [39] and dental 
porcelains [40, 41].  
x Orthopaedic applications: Osteoarthritis and rheumatoid arthritis can lead to 
disturbances in the movement of joints such as hips, knees and elbows along with 
considerable amounts of pain.  Normally used for load bearing applications, metallic, 
ceramic and polymeric biomaterials have been used for replacements of such load-
bearing joints. Recently developed orthopaedic biomaterials include Zr, Ti and other 
ceramics used for joint replacements [42], porous poly (para-phenylene) scaffolds 
[43], whereas hydroxyapatite assisted implants have been used for bone bonding 
applications [44, 45].  
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x Cardiovascular applications: The most important criteria for the cardiovascular 
implants is to have a unique blood biocompatibility so that the host body does not 
reject the implant and to avoid the occurrence of an adverse thrombogenic (clotting) 
or hemodynamic (blood flow) response. Cardiovascular applications include materials 
for heart valves, artificial heart implants, vascular grafts and stents, and ventricular 
assisting devices. Materials used for fabrication of cardio-vascular implants include: 
polyhydroxyalkanoates [46, 47], synthetic degradable polymers such as Polyglycolic 
acid (PGA), Polylactic acid (PLA) and Poly-E-caprolactone (PCL) [48-50], stainless 
steel, Co-Cr alloys and titanium. 
x Drug-delivery systems: Many attempts have been made to incorporate drug 
reservoirs into implantable devices for a sustained and preferably controlled release. 
Recent evolution of implantable drug delivery systems includes Poly (lactic-co-
glycolic acid) (PLGA) based biodegradable polymers [51], silk fibroin [52] and 
chitosan [53]. 
x Ophthalmics: The tissues of the eye can suffer from several diseases leading to 
reduced vision and cause blindness. Researchers are continuing into the replacement 
of the damaged eye tissue with an intraocular lens made of natural or synthetic 
materials like silk fibroin and chitosan [54-56].  
 
2.8 The Necessity of Biomaterials in Bone Tissue Engineering 
 
Bone is a highly vascularised tissue that can remodel itself throughout its life. Apart from 
giving structural functions to the body, it is also involved in maintaining homeostasis of the 
body through its storage of Ca and P ions and by regulating the electrolyte concentrations in 
the body. Due to its high regenerative capacity, majority fractures heal well without the need 
for external intervention. In spite of this, bone is often prone to injuries due to trauma, aging 
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or diseases and requires surgical intervention. The US data on bone therapy market report 
estimated 6.2 million bone fractures every year, of which 10% cases fail to heal properly 
[57]. It is estimated that around 10 million people are affected by osteoporosis and the 
number is likely to increase to 14 million by 2020 [58, 59]. Recent statistics from the 
National Osteoporosis Society (NOS) report an estimated expenditure of £1.73 billion for 
treating hip fractures in the United States and massive amounts spent by the National Health 
Service (NHS) for treating osteoporosis related fractures [60]. Furthermore, it is estimated 
that approximately 2.2 billion bone graft procedures are being performed worldwide, 
annually to repair bone defects [61]. Currently, the gold standard treatment involves the use 
of autografts obtained by harvesting the donor bone from a non-load-bearing site in the 
patient and transplanting into the defective site. There has been a growing need for 
considerable autologous bone grafting in spinal fusion, which was reported to be the 19th 
most common in-patient procedure in the United States in 2003 [62]. Autologous bone 
transplantation gives the best clinical outcome, as there remain few complications related to 
immunity and diseases, unlike the allogenic bone grafts from cadavers. Unfortunately, there 
is a very short supply of autografts and considerable donor site morbidity associated with its 
harvest [63, 64]. Therefore, it is essential to find ideal substitutes and materials for restoring 
the normal functioning of the damaged bone tissue. 
The success of orthopaedic biomaterials in healing bone defects in the past few decades has 
led to further developments in this field. While materials proposed for implantation in the 
past were designed to be ‘bio-inert’, materials scientists have now moved towards the design 
of ‘bioactive’ materials that establish bonding with biological molecules or cells and 
regenerate tissues [65, 66]. Applications of these bioactive materials are many, including 
craniofacial surgery, dental and fracture fixation and total joint arthroplasty. For orthopaedic 
applications, biomaterials should have the properties of biocompatibility, possess adequate 
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mechanical properties with high corrosion and wear/tear resistance and provide bioactive 
surfaces for osseointegration upon implantation. For implantation in bone applications, 
materials should preferably be osteoinductive (capable of promoting the differentiation of 
progenitor cells down an osteoblastic lineage), osteoconductive (support bone growth and 
encourage the ingrowth of surrounding bone), and capable of osseointegration (integrate into 
surrounding bone). The ideal bioactive material is one which gets resorbed and replaced over 
time by the body's own newly regenerated biological tissue [65]. The materials used for 
orthopaedic surgery include bioactive inorganic materials, polymers, hydrogels, fabrics, 
ceramics, composite materials, metals and natural materials [67]. The major requirement of 
prosthetics is their use in load bearing applications and the criteria of long-term performance. 
However, this review focuses in the directed use of biomaterials as orthopaedic implants for 
load bearing applications. 
 
2.8.1 Metallic implants in orthopaedics 
 
The increasing trend to replace defective tissue in orthopaedics has come from the use of 
metals, especially in total joint replacements such as hip and knee. Unfortunately, the current 
available metallic materials have been found to fail in long-term usage, as the load bearing 
implants must satisfy specific properties to be used for long-term applications. The desired 
metallic implants need to fulfil the mechanical and non-mechanical criteria to be used as 
devices for bone repair and healing. Table 2.2 describes the properties that make the metal a 
suitable implant material [68]. The currently used major groups of load bearing metal 
implants for applications in the biomedical field include, stainless steel, cobalt-chromium 
alloys and titanium and its alloys.  
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2.8.1.1 Stainless steel 
Stainless steel is widely used in orthopaedic applications due to its low cost, superior 
fabrication properties, high corrosion resistance, and its availability [76]. Stainless steel is the 
generic name for a number of steels used primarily because of their resistance to a wide range 
of corrosive agents. This resistance is due to their high Cr content (17-20 wt%) that forms a 
chromium oxide coating (Cr2O3). The Cr in the stainless steel has a great affinity for oxygen 
and hence leads to formation of a passive, highly adhesive and self-healing chromium oxide 
layer on the surface of the steel [74]. The main stainless steel used for manufacturing 
implants is an austenitic type called 316L [77], which is widely used in trauma-related 
temporary devices such as fracture plates, screws and hip nails. However, austenitic stainless 
Requirements Implications 
Mechanical properties 
1. Long fatigue life [68] Implant mechanical failure and revision surgery 
2. Adequate strength [69] Implant failure, pain to patient and revision surgery 
3. Modulus equivalent to that of bone 
[69, 70] 
Stress shielding effect, loosening failure, revision 
surgery 
4. High wear resistance [71] Implant loosening, severe inflammatory response, 
destruction of the healthy bone producing debris 
which can go to blood 
Non-mechanical properties 
5. High corrosion resistance [72] Releasing non-compatible metallic ions and allergic 
reactions 
6. Biocompatibility [73, 74] Body reaction and adverse effects in the organic 
system  
7. Osseointegration [69, 75] Fibrous tissue between the bone and the implant, 
not well integration of the bone and implant and 
finally implant loosening.  
Table 2.2. Properties of a desirable metallic implant, along with their effects from inadequate 
functionality (67). 
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steel has a very poor wear resistance with a high modulus of 200 GPa compared to the natural 
bone, resulting in rapid loosening of the implant due to the debris generated that creates risks 
of allergic reactions [78], which limits its use for medical applications.  
 
2.8.1.2 Cobalt-Chromium alloys 
After stainless steel, Co-based alloys are the most commonly used implants in orthopaedic 
applications. They can form a passive oxide layer in a chloride-containing environment and 
hence are highly resistant to corrosion within the human body [79, 80]. There are two types 
of Co-Cr alloys commonly used in dentistry and artificial joints, and in making the stems of 
prosthesis respectively, namely Co-Cr-Mo and Co-Ni-Cr-Mo. These materials have better 
mechanical properties compared with stainless steel [74, 79], such as high resistance to 
fatigue and a good wear and corrosion resistance. However, these alloys may release 
elements like Cr and Co during the process of corrosion [73], which are even more toxic than 
the corrosion products of stainless steel. Moreover, their high elastic modulus of 220-230 
GPa, which is almost similar to that of stainless steel (approximately 200 GPa), makes them 
unsuitable for implant purposes.    
 
2.8.1.3 Ti and its alloys      
Ti and its alloys contain many desirable characteristics of an implant material, which make 
them excellent metals for orthopaedic applications over stainless steel and Co-Cr alloys [70, 
81]. The high strength, good resistance to corrosion, complete inertness to body environment, 
enhanced biocompatibility, moderate elastic modulus of approximately 110 GPa displayed by 
Ti are suitable choice for implantation. Ti and its alloys have extensive applications in 
biomedical field, especially in load bearing applications such as artificial hip joints and 
artificial knee joints, and as stents, dental implants, bone plates and screws. The 
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commercially available pure Ti (CP Ti) and Ti–6Al–4V ELI (Ti64) are the most commonly 
used titanium materials for implant applications. But the long-term use of these materials may 
release of certain unwanted ions like aluminium and vanadium which are associated with 
diseases like Alzheimer and neuropathy [70, 74].  Further, Ti alloys suffer from severe wear 
in the presence of friction from other metals or from itself [82]. Therefore their application 
becomes limited only to the locations where wear resistance is of little or no importance. 
 
2.8.2 Mg and Mg alloys as biodegradable implants 
For many years, stainless steel, cobalt-chromium, and titanium alloys have been the primary 
biomaterials used for load-bearing applications. However, such conventional metallic 
materials are biocompatible but not biodegradable, and they provide only short-term 
structural support. Biomaterials that can be reabsorbed into the body after healing, like Mg-
based alloys, provide a number of benefits over traditional permanent implants. The 
disadvantages of using conventional surgical alloys, like stainless steel, cobalt, chromium and 
nickel-based alloys have been already discussed in the previous section. Conversely, Mg has 
many attractive physical characteristics very close to that of the human bone (Table 2.3).  
Mg has high specific strength that increases its load bearing capacity. Its low elastic modulus 
improves stress-shielding effects between the bone and the implant material. Mg is essential 
for human metabolism and is associated to various pathological conditions [5]. Mg is the 
second most common intracellular ion in our body and serves as a cofactor for many 
enzymatic reactions ranging from muscle contraction to neuronal control [83]. Almost 53% 
of Mg in the body is stored in bone in the form of hydroxyapatite in the inorganic matrix 
[84]. Magnesium-based materials were first introduced by Lambotte as a pure Mg plate, 
along with gold-plated steel nails, to secure lower leg bone fractures [8, 85]. However, the 
high rate of in vivo corrosion of the implant made it degrade entirely in as early as 8 days. 
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Since then, numerous attempts have been made to increase the corrosion resistance of Mg 
implants by studying its corrosion properties both in vitro [86] and in vivo [6]. Eventually 
these studies highlighted other beneficial in vivo properties of Mg and its alloys like its ability 
to stimulate bone growth and healing [6]. Furthermore, the corrosion and degradation 
products of Mg are harmless and are excreted through urine [87].  
Properties 
 
Natural 
bone 
Mg Ti alloy Co-Cr 
alloy 
Stainless 
steel 
Synthetic 
HAP 
Density (g/cm3) 1.8-2.1 1.74-2.0 4.4-4.5 8.3-9.2 7.9-8.1 3.1 
Elastic modulus 
(GPa) 
3-20 41-45 110-117 230 189-205 73-117 
Compressive yield 
strength (MPa) 
130-180 65-100 758- 
1117 
450-1000 170-310 600 
Fracture toughness 
(MPam1/2) 
3-6 15-40 55-115 N/A 50-200 0.7 
 
Table 2.3. Summary of the physical and mechanical properties of various implant materials in 
comparison to natural bone (8). 
 
However, the major drawback of using Mg as implant material is its low corrosion resistance 
which leads to rapid release of degradation products and causes a reduction in the mechanical 
integrity of the implant, even before the defective bone is healed properly [8]. The high 
corrosion rate also leads to rapid production of hydrogen gas leading to formation of gas 
bubbles that can accumulate around and cause implant loosening. The localised formation of 
hydrogen gas also increases the pH around the implant area. To successfully use Mg alloys as 
implant material, their properties should be such that the cells can synthesise and deposit 
extracellular matrix (ECM) for their support and function before the structural integrity of the 
implant is compromised. To date, many elements have been explored for alloying pure Mg to 
improve its in vitro and in vivo performance by studying the degradation and biological 
behaviour of its alloys like AZ31 (Mg–3Al–1Zn), AZ91/AZ91D (Mg–9Al–1Zn), WE43 
(Mg–4Y–3RE) and LAE442 (Mg–4Li–4Al–2RE) [12, 88, 89]. However, many of these 
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alloys contribute to the cell cytotoxicity because of its elemental constitutions [90-93]. 
Hence, development of new biodegradable Mg alloys with the combination of completely 
biocompatible alloying elements is necessary. Further, several surface modification methods 
have also been established to improve the corrosion performance of Mg alloys and to enhance 
the cellular properties upon its implantation.  
 
2.9 Surface Modification of Magnesium Alloys 
As discussed above, Mg-based implants are becoming promising candidates for fracture 
fixation because of their stress shielding capacity during fracture healing and bone 
remodelling. Mg-based biodegradable implants are now being used for cardiovascular stents 
and have also been successfully tested in animal models [94, 95] and has progressed with 
clinical trials in patients with peripheral arterial obstructions and coronary artery disease [96, 
97]. However, much effort is required to avoid its fast degradation in vivo for orthopaedic 
applications in fracture fixation. The following are the main concerns regarding their 
orthopaedic applications [87, 98].  
1. Rapid degradation before the time required for fracture healing, leading to insufficient 
mechanical support for bone fracture fixation; 
2. High degradation resulting in local accumulation of alkaline ions that induces local 
inflammation after implantation; 
3. Rapid release of Mg ions due to high degradation rate causing adverse effects, such as 
diarrhoea and abdominal cramps, leading to renal failure.  
To overcome these drawbacks, surface modification methods such as coatings on Mg-based 
materials are proven to be efficient to control the degradation and corrosion rate [17, 99, 
100]. The surface modification methods developed in Mg alloys to date can be divided into 
two major groups - chemical modification and physical modification. 
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2.9.1 Chemical modification 
Chemical modification involving the use of chemical or electrochemical treatments to cover 
the surface of Mg alloys is basically used to remove the native oxide layer that is formed due 
to high reactivity of Mg matrix leading to surface corrosion [101, 102]. The surface 
morphology can be easily controlled at as low as nanometre levels. Moreover, chemical 
methods can be manipulated easily and are generally cost effective without the requirement 
for special facilities. The following are several methods of chemical modification. 
 
2.9.1.1 Acid etching 
Acid etching removes the native and porous oxide films through the creation of uniform and 
compact layers, leading to the minimisation of local degradation behaviour. Acids such as 
phosphoric acid (H3PO4) [17] and sulphuric acid (H2SO4) [103] have been used so far for this 
purpose. A dense and homogenous layer of Mg3(PO4)2 coating was found on the surface of 
the treated samples that showed much lower degradation rate as compared to the control [17, 
103].  
 
2.9.1.2 Alkaline treatment 
Alkaline treatment of Mg substrates leads to formation of a thin layer of passive film on the 
surface of the alloy during their immersion in cell culture medium, which inhibits the 
increase of pH [104]. In addition to alkali, other alkaline solutions such as Na2HPO4, Na2CO3 
and NaHCO3 [105] have been used to modify the Mg alloy surfaces. The treatment of Mg 
alloys with alkali and alkaline solutions leads to the formation of a passive layer in the form 
of Mg(OH)2, MgCO3, and MgO. The resistance to degradation depends on the thickness of 
the film formed, which further depends on the surface roughness of the alloy. Hence, surface 
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topography of the alloy needs to be controlled during alkaline treatments for desirable 
protective films. 
 
2.9.1.3 Fluoride treatment 
Fluorine is one of the most important components of skeleton and teeth in humans [106] and 
hence its use can be beneficial to the skeletal system. Fluoride treatment leads to replacement 
of the original oxide layer in Mg alloys, with a thin and homogeneous layer of magnesium 
fluoride (MgF2) that shows higher corrosion resistance. This layer is found to have high 
density, of lower solubility in aqueous solution and harmless to the host organism [107]. Also 
used in Mg alloy coatings are MgF2, ammonium fluoride (NH4F) solution [103] and 
hydrogen fluoride (HF) [108] to improve the corrosion resistance of pure Mg.  
Apart from the chemical techniques, many other electrochemical methods were developed to 
improve the corrosion property of Mg alloy such as anodising coating [109], electron beam 
treatments [110] and ion implantation [111-113] that uses different applied high power 
voltages to reduce the degradation rate of Mg in immersed state.  
 
2.9.2 Physical modification 
In the physical approach of surface modification, there is no chemical bond formation 
between the outer coating and the surface of the substrate. However, it induces structure 
modification of the entire scaffold by introducing new layers or phase such as polymers and 
inorganic compounds [114-116] leading to better performance in the corrosion resistance of 
the Mg scaffolds.  
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2.9.2.1 Apatite coating 
Apatite is one of the main component of natural bone matrix (Section 2.3), which is used 
mostly in the form of hydroxyapatite [HA, Ca10(PO4)6(OH)2]. Apatite can make a remarkable 
impact on the growth of fractured bone due to its excellent mechanical and biological 
properties like relative low solubility with high thermal stability [114] and cell adhesion with 
osteoinduction [117] respectively. HA is highly bioactive and thus can enhance bone bonding 
to the implant surface and prevent formation of fibrous tissue in and around the implant area 
[118]. To date, HA has been used by itself or in combination with other chemicals like 
fluorine doped HA [119, 120] to enhance the bioactivity of Mg alloys. However, HA has a 
relative high dissolution rate and low adhesion, which make it unfavourable for long-term 
stability of the implants.  
 
2.9.2.2 Organic polymer coatings 
Many polymers have been used as coatings for biomedical applications as degradable 
polymers can insulate the solution and substrates more effectively compared with other 
surface coatings. Polymers have been used in the form of PGLA [poly(lactide-co-glycolide)] 
[115] and PCL (polycaprolactone) [99] coatings on Mg alloy implants to control their 
bioactivity. However, pre-treatment steps are required to use these polymers as coatings so 
that it can provide the ability of tight cell adhesion. For this reason, it is crucial to seek more 
suitable polymers as protective layers for developing medical implants. 
 
2.9.2.3 Metal oxide coatings 
Metal oxides are good choices for modifying the degradation properties of Mg alloys as the 
oxidative forms of some non-toxic metal elements can form a protective deposition layer on 
the alloy surface. Metallic coatings like Titanium oxide (TiO2) films [121] and Cerium oxide 
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(CeO2) coatings [122, 123] have been reported to improve the biodegradation properties of 
Mg alloys. The effects of coating showed a decrease in the corrosion results by about 30 
times for the composite-coated samples when compared to the uncoated ones. 
 
2.9.2.4 Morphological surface modifications 
Morphological surface modifications are done to create three-dimensional features in the 
form of pores, gratings, columns, dots, pits and random surface roughness [124, 125]. 
Morphological modification of Mg alloys can be done by mechanical and heat treatment like 
deep rolling, shot peening and roller burnishing [126] and involves physical treatment, 
shaping or removal of the material’s surface. The main aim of these kinds of mechanical 
modification is to attain specific surface topographies and roughness, remove surface 
contaminants and to improve cell adhesion. 
 
2.9.2.5 Bioactive surface modifications 
Bioactive and functional surface modification of Mg alloys is done to make them suitable to 
react with ions and molecules and to activate/promote osteoconduction and osseointegration. 
In addition to the above chemical and physical surface coating methods, several other coating 
procedures also include immobilisation techniques that can reduce cytotoxicity of the alloy 
and enhance their cytocompatibility. Many authors have reported several coating agents in 
the form of proteins and peptides that are bioactive and can influence osseointegration. 
Among them, Collagen type I (Col-I) [127, 128], Bone Morphogenetic Protein-2 (BMP-2) 
[129, 130] and calcium phosphate [131, 132] are the most used agents for coating. Col-I, 
extracted from rat-tail, has been used as coating agent in my work. The description of this 
protein is given below. 
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Col-I is the predominant component of connective tissue matrix. It is one of the major 
constituents of bone ECM comprising 90% of the protein matrix of adult bone, and serves as 
a basis for mineral scaffold [133]. Col-I has three polypeptide chains (α chains) that form a 
unique triple-helical structure. It is a heterotrimer of two α1 and one α2 chains, α1(I) is more 
conserved than the α(I) chain. It contains an uninterrupted triple helix of approximately 300 
nm in length and 1.5 nm in diameter flanked by short non-helical telopeptides. Each chain 
has a repeating Gly-Xaa-Yaa sequence, in which Xaa and Yaa can be any amino acid but are 
frequently the amino acids proline and hydroxyproline. It is found predominantly in skin, 
bone, tendon, ligaments and cornea.  
 
 
Figure 2.9. Figure illustrating the steps of Col-I fibril formation [134]. Col-I affects the 
attachment and differentiation of osteoblast cells by binding to integrins [135-138]. Earlier 
studies illustrated that bone cells adhere to Col-I because it contains RGD sequence that are 
recognised by integrins. However more recent studies on this protein showed that its α1 chain 
contains DGEA motif which is recognised by integrin α2β1 [136, 139]. 
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The telopeptide does not contain the Gly-Xaa-Yaa conserved sequence and does not take the 
form of triple helix although it is very important in fibril formation. Col-I self-assemble into 
fibrils [134] and the process is driven by loss of solvent molecules from the protein surface. 
This assembly of monomers into fibrils minimises the surface area/volume ratio. The fibril 
formation occurs after the soluble procollagens are converted into collagens by specific 
enzymatic cleavage of terminal propeptides by the procollagen metalloproteinases (Figure 
2.9). 
 
2.10 Summary 
The degradation property of Mg-based alloy has become the most important aspect with 
regard to its success, because of the many advantages specified in this review. Ideally the 
coating itself should degrade gradually, helping to control the overall corrosion process, 
while leaving no harmful traces of the corroded products. Further, no clear evidence exists 
regarding the osseointegration and enhanced cellular response to surface modified alloys of 
Mg containing different elemental constitutions of Zr, Ca and Sr. It is important to understand 
the specific role of elemental constitutions of different concentrations of alloyed elements in 
Mg alloys and their cellular response when coated with Col-I. This forms the basis of the 
objective of this study. 
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Chapter 3 
Materials and Experimental Techniques 
 
3.1 Sample Preparation 
The Mg-Zr-Sr/Ca alloys were prepared by casting from melts of pure Mg (99.9%), Ca 
(99.9%) and master Mg-33Zr and Mg-30Sr alloys. The contamination of molten Mg by Fe 
was avoided by using a coated steel crucible and the Mg alloys were melted under an 
atmosphere of high purity argon. The melt was maintained by stirring for 30 min and was 
casted into cylindrical steel dies at 700 °C after preheating to 250 °C, with an inner diameter 
of 22 mm. This Mg alloy ingots were machined to remove the outer layer to obtain 
cylindrical bars with diameters of 9 mm and 5 mm by electrical discharge machining (EDM). 
Disc samples with a diameter of 9 mm and thickness of 2 mm were machined along the long 
axis of the cylindrical bars for microstructure characterisation and in vitro cell culture study. 
Cylindrical samples with a diameter of 5 mm and length of 10 mm were machined in the 
same way for the compressive test. Similarly, cylindrical samples with a diameter of 2 mm 
and length of 4 mm were cut along the long axis for their in vivo assessment. The chemical 
compositions of the alloys were determined by wavelength dispersive X-Ray fluorescence 
(WDXRF) spectroscopy (S4 Pioneer, Bruker, Germany). 
 
3.2 Microstructure, Mechanical and Surface Properties 
3.2.1 XRD and compressive test 
X-Ray diffraction (XRD) analysis was carried out to characterise the microstructural phases 
of the Mg alloys. To characterise the phase constituents of the alloys, XRD analysis was 
performed at 40 kV and 30 mA with a scanning rate of 0.05 degree 2 theta per min. The scan 
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range was from 20 to 80 degrees. To evaluate the mechanical properties, compressive tests 
were carried out at an initial strain rate of 10-3 s-1 using an Instron universal tester equipped 
with a video extensometer (Instron 5567, USA). 
 
3.2.2 Optical microstructure and surface morphology by SEM 
All the Mg alloy samples for optical microscopic observation were etched with picric acid (a 
solution of 1.5 g picric acid, 25 ml ethanol, 5 ml acetic acid and 110 ml distilled water). The 
surface morphology of the Mg-based alloys was investigated using SEM (3400N Hitachi, 
Japan) after gold coating in an ion sputter coater SC7620 (Polaron Range, UK). 
 
3.2.3 Surface roughness and surface free energy 
Surface roughness (Ra) measurement [140] of the bare and coated Mg-based alloys was done 
using stylus profilometry (Taylor Hobson, London, UK). Five measurements were performed 
for each group of samples to evaluate the average Ra values. The free surface energy of the 
bare and coated alloys was estimated by measuring the static contact angle (T) using 2 μL of 
water and glycerol with a sessile drop method in a video-camera based OCA 40 micro, 
DataPhysics (Germany). Average values of T for left and right side of the drop were 
measured by Wu approach [141] for each solvent at three different positions on each alloy 
surface. This T value was used for calculation of the free surface energy. Surface energies of 
the substrates were calculated using SCA20_U software (provided by the manufacturers) 
applying the Wu and Owens- Wendt method [141]. Average results from three independent 
experiments were used for calculating the mean surface energy of each alloy. 
 
3.2.4 Hydrogen gas evolution 
The hydrogen gas evolution by Mg alloys was measured by following the protocol described 
by Aung and Zhou (2010) [142]. The Mg alloys were immersed in simulated body fluid 
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(SBF) and the volume of hydrogen gas generated was measured as a function of immersion 
time. Disc samples of 9 mm diameter and 2 mm thickness were used for the hydrogen 
evolution tests. The Mg alloy samples were mounted in epoxy resin with an exposed area of 
0.64 cm2 (9 mm diameter). The mounted sample with an exposed area upwards was 
immersed into SBF and incubated at 37 °C. A funnel and burette were used to cover the 
sample and collect the hydrogen gas produced [142]. The volume of hydrogen gas was 
measured using the burette. 
 
3.3 Collagen Type-I Extraction, Characterisation and Coating 
3.3.1 Protein extraction, precipitation and estimation 
The Col-I was extracted according to the protocol described by Rajan et al. [143]. In brief, 
Col-I was extracted from rat-tail tendons in acetic acid solution to obtain a crude collagen. It 
was then dissolved in 0.25 N acetic acid and then precipitated in 2.4 M NaCl to obtain a type-
I collagen. The dissolved collagen was then dialysed against 0.25 N acetic acid for 48 h at 4 
°C, followed by lyophilisation. The samples were stored in -80 °C for further use. For 
experimental use, samples were reconstituted in 0.25 N acetic acid and estimated by Sirius 
Red method [144].  
 
3.3.2 SDS-PAGE and Western blotting 
The reconstituted Col-I was subjected to Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) on 8% gel to visualise the Col-I bands. Standard Col-I was 
obtained from CSIRO (Monash University campus, Australia). The polyacrylamide gel 
contained 1.5M (pH 8.8) and 1M (pH 6.8) Urea (Bio-Rad, Hercules, California, US) for 
resolving and stacking gel, respectively, with 30% Acrylamide (Bio-Rad), 10% Ammonium 
Persulfate (APS) (Bio-Rad) and 0.2% TEMED (Sigma Chemicals, St. Louis, Missouri, US). 
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Proteins were visualised by Coomassie Brilliant Blue R-250 staining (Bio-Rad). Images were 
acquired using Fluor- S Multi Imager (Bio-Rad).  The polyacrylamide gel was electroblotted 
onto PVDF membrane and blocked overnight in 5% Bovine Serum Albumin (BSA) (Sigma 
Aldrich, St. Louis, MO, USA) in Tris-buffered saline (TBS) containing 0.1% Tween- 20. 
Membranes were incubated with primary antibody (monoclonal IgG1 anti-bovine Col 
antibody made in mice) (Sigma Aldrich, St. Louis, MO, USA) for 2 h, followed by 
horseradish peroxidase (HRP) tagged secondary antibody (rabbit anti-mouse Ig) (Sigma 
Aldrich, St. Louis, MO, USA) in TBS containing 0.1% Tween-20 for 1 h. Bound antibodies 
were visualised using a chemi-luminescence kit (Roche Applied Science Inc., Penzberg, 
Germany). 
 
3.3.3 Dip coating 
The Mg alloys were dip coated according to the procedure described by Geißler et al. [127]. 
The lyophilised Col-I of concentration 5 μg/μL was dissolved in 0.25 N acetic acid with 
equal volume of 133 mM phosphate buffer (pH 6.5). The solution was then centrifuged at 
5000 X g at 4 °C for 5 min. The alloys were then coated with Col-I solution using a Single 
Dip Coater (Model No SDC 2007C, Apex Instruments Co., Kolkata, India) using SDC 
Software provided by the instrument suppliers. The alloys were dipped with dipping/lifting 
speeds of 60 mm/min for a waiting time of 5 min. Samples were then dried at room 
temperature. 
 
3.3.4 Characterisation of protein and coated surface by FT-IR 
The standard Col-I and Col-I coated alloys were examined for transmission with an FT-IR 
spectrophotometer (Vexter 70, Bruker, Germany) using the attenuated total reflectance 
(ATR) method. For spectral acquisition, the system was used in point mode with a 4.0 cm-1 
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resolution at 32 scans in ATR spectrum mode. Spectra were analysed using the OPUS 5.5 
software provided by the instrument suppliers. 
 
3.4 Cell Culture 
3.4.1 Cell line maintenance 
Mouse osteoblast MC3T3-E1 cell line of subclone 4 from ATCC (American Type Culture 
Cultivation, USA) was used for the culture experiments. The cells were maintained in α-
MEM (Invitrogen, Gibco, USA) supplemented with 10% fetal calf serum, 100 U mL-1 
penicillin and 100 μg mL-1 streptomycin at 37 °C in a humidified atmosphere of 95% air and 
5% CO2. The cells were used within 4 to 5 passages after revival from frozen condition 
where they were maintained in original condition.  
 
3.4.2 MTT assay for cell viability 
The biocompatibility of bare and coated Mg alloys was evaluated using the indirect contact 
method [145] according to ISO 10993-5 [146].  
 
3.4.2.1 Preparation of alloy extract  
Alloy extracts were prepared in alpha-MEM complete medium supplemented with 10% fetal 
calf serum (FCS), 100 U mL-1 penicillin and 100 μg mL-1 streptomycin at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2 for 24 h with surface area of alloy to media 
ratio of 0.6 cm2 mL-1. The supernatant media extract from each sample was collected and 
filter-sterilised with a 0.22 μ filter (Merck Millipore, Darmstadt, Germany). Alpha-MEM 
complete medium was used as negative control while alpha-MEM complete medium with 
0.64% phenol was used as a positive control by incubating them under similar conditions.  
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3.4.2.2 Cell culture  
Cell culture was done by suspending 5 X 103 cells in 100 μL complete media on a 96-welled 
tissue culture plate (TPP, Switzerland). Cells were incubated for 30 min at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2. After which additional 2 mL media was 
added to each well and incubated for 4 h. The media was then removed and the discs were 
washed twice with PBS to remove the non-adherent cells. The percentage of viable cells on 
the culture plate was calculated by performing MTT assay.  
 
3.4.2.3 MTT assay 
After incubation for 4 h, the culture media was replaced with 100 μL of respective alloy and 
control extracts. The cells were further incubated for 12 h after which MTT (3- (4, 5-Di-
methylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide) (Sigma) assay [147] was performed. 
The experiments were carried out in triplicates. A standard curve was generated using 
different cell numbers. The optical density (OD) of all the samples and the control were 
converted to respective cell numbers and the relative cell viability for each sample was 
calculated as:  
Relative Cell Viability = (ODtest/ODnegative control) X 100% 
 
3.5 Techniques for Gene Profiling 
3.5.1 Cell culture for gene expression studies 
Due to early degradable nature of Mg alloys under in vitro conditions, the gene expression 
studies were performed by indirect method of cell culture. Cells were plated using complete 
media as described above in a tissue culture T25 flask. After allowing initial adhesion of 4 h, 
the complete media was replaced very gently by alloy extracts without disturbing the cells. 
They were then incubated in standard conditions for 24 h (1d) and 7 days for gene expression 
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studies. The alloy extract was supplemented with conditioned media at an interval of 2 days 
for 7 days culture to maintain the media volume. 
 
3.5.2 Total RNA isolation 
High quality total RNA was extracted and purified from the cells cultured with each alloy 
extract different time points of 24 h and 7 days using the Qiagen RNA plus kit (QIAGEN, 
USA) as per the manufacturer’s protocol. In brief, culture flasks were washed with PBS with 
subsequent addition of 600 μL of Buffer RLT Plus (with β-mercapto ethanol). The culture 
flasks were scrapped with a rubber policeman and the lysate was passed 5 times through a 20-
gauge needle. The lysate was then passed through a gDNA Eliminator spin column. This 
column, in combination with the optimised high-salt buffer, allows efficient removal of 
genomic DNA. Ethanol was added to the flow-through to provide appropriate binding 
conditions for RNA, and the sample was then applied to an RNeasy spin column where total 
RNA binds to the membrane and the contaminants are efficiently washed away with Buffer 
RW1 and RPE. High quality RNA was then diluted in 50 μL of diethyl pyrocarbonate 
(DEPC) treated ddH2O. RNA from two separate experiments was isolated for preparing 
cDNA.  
 
3.5.3 RNA quality check and quantification  
The nucleic acid concentration of the RNA preparation was determined by measuring the 
absorbance at 260 nm using a Nanodrop spectrophotometer ND1000 (Thermo Scientific, 
USA). 50 μg of double stranded DNA, 33 μg of single stranded DNA (primers for PCR) and 
40 μg of single stranded RNA was taken to be equal to 1.0  OD260. Purity was checked by 
taking the ratio of the absorbance at 260 nm to 280 nm. The quantified RNA was checked on 
0.8% agarose gel electrophoresis for its purity.  
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3.5.4 cDNA synthesis/reverse –transcription reaction 
cDNA synthesis was done using superscript IIITM reverse transcriptase (RT) enzyme 
(Invitrogen Life Sciences, USA). 2 μg RNA for each alloy type and for each time point was 
added to a reaction mixture containing 10 mM deoxyribonucleotide triphosphate mix (dNTP) 
and 50 μM oligodT (Oligo dinucleotide) for first strand synthesis at 65 °C for 5 min after 
which it was instantly placed on ice for approximately 5 min. A master mix consisting 5X 
reaction buffer, 0.1 M DTT (Di-thio-threitol), RNase inhibitor and superscript IIITM RT 
enzyme was prepared and added to the first strand synthesised mixture by incubating at 50 °C 
for 1 h followed by inactivation of RT at 70 °C for 15 min. cDNA synthesis was done for 
both the RNA preparations and used for real time PCR experiments. DEPC-treated water was 
used for the experiments.  
 
3.5.5 Quantitative real time polymerase chain reaction (RT-PCR) 
A 10 uL reaction mixture each consisting of triplicate samples of cDNA, specific primer mix 
and Power SYBR green Master mix (ABI systems, USA) was setup in each well of a 384-
well reaction plate (ABI Systems, USA). Forward and reverse primers, specific for genes, 
were adapted from Sista et al. (2013) [148]. cDNA for GAPDH was used as endogenous 
control for calculating fold differences in RNA levels of cells cultured in the alloy extracts by 
the 2-''CT method. Table 3.1 shows the list of forward and reverse primers for genes used. 
After sealing the reaction with optical adhesive cover (ABI Systems, USA) the PCR plate 
was placed in Applied Biosystems 7900HT Fast real time PCR system machine (Applied 
Biosystems, USA). The cycle conditions were set up as detailed: 50 °C for initial heating of 2 
min, 95 °C for 1 min, 40 cycles of 95 °C for 30 s followed by 60 °C for 30 s and 72 °C 
elongation for 30 s each. A dissolution curve analysis was done at the end of every reaction to  
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Table 3.1. Forward and reverse primers of genes used for quantitative RT-PCR experiments. 
 
check for the specificity of the final product formed. The entire quantitative real time PCR 
was done for duplicate RNA samples for calculating the statistical significance of the data.  
 
3.5.6 Agarose gel electrophoresis 
Agarose gel electrophoresis is used for checking the purity of isolated nucleic acids. In this 
study, the purity of the isolated RNA was checked using 0.8% agarose gel prepared in TBE 
Gene Primers (5’-3’) Product 
length (bp) 
GAPDH Fwd- AGC GAG ACC CCA CTA ACA TCA 21 
 Rev– CTT TTG GCT CCA CCC TTC AAG T 22 
ALP Fwd– ACC CGG CTG GAG ATG GAC AAA T 22 
 Rev– TTC ACG CCA CAC AAG TAG GCA 21 
Collagen type-I Fwd– CTC CTG ACG CAT GGC CAA GAA 21 
 Rev– TCA AGC ATA CCT CGG GTT TCC A 22 
Osteopontin Fwd– TGA TTC TGG CAG CTC AGA GGA 21 
 Rev– CAT TCT GTG GCG CAA GGA GAT T 22 
Osteonectin Fwd– ATG TCC TGG TCA CCT TGT ACG A 22 
 Rev– TCC AGG CGC TTC TCA TTC TCA T 22 
Bone sialoprotein Fwd– ACC GGC CAC GCT ACT TTC TTT A 22 
 Rev– GGA ACT ATC GCC GTC TCC ATT T 22 
Osteocalcin Fwd– AGC AGG AGG GCA ATA AGG TAG T 22 
 Rev– TCG TCA CAA GCA GGG TTA AGC 21 
BMP2 Fwd– TGG AAT GAC TGG ATC GTG GCA C 22 
 Rev– ACA TGG AGA TTG CGC TGA GCT C 22 
Fibronectin Fwd– TGC AGT GGC TGA AGT CGC AAG G 22 
 Rev– GGG CTC CCC GTT TGA ATT GCC A 22 
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buffer (Tris boric acid). Ethidium bromide (EtBr) was added just before solidification of the 
gel after boiling the agarose solution for ~10 mins. The solution was then poured into a 
casting tray with multi-welled comb and allowed to solidify at room temperature. The 
samples were then loaded into each well mixed with 5X loading dye consisting of 
bromophenol blue (BPP), xylene cyanol and β-mercaptoethanol. EtBr is a chelating agent, 
which chelates between the bases present in the double stranded helix of DNA and RNA. The 
gel was run at a constant voltage of 100V for 1 h. The RNA bands were visualised by 
exposing the gel to UV lamp. Similar procedure was used for checking the specificity of the 
final product formed after RT-PCR where a 1% agarose gel was prepared. 
 
3.6 Animal Experiments 
3.6.1 Implant preparation and surgery 
Prior to surgery all implants were sonicated in 2% chromium oxide for 20-30 min followed 
by 10 min wash each with acetone, ethanol and distilled water respectively, air-dried and UV 
sterilized. Male New Zealand White rabbits of approximate age 4–6 months were used for in 
vivo studies. Three animals were used for each alloy and as controls in each experiment. 
Biologically duplicate experiments were carried out for statistical analysis. Alloys were 
implanted in the hole drilled in the lower end of the femur bone of rabbits as per the surgical 
procedures cleared by the institutional animal ethics committee of Deakin University and 
CSIR-CCMB.  
 
3.6.2 Blood sample collection, blood cell count and blood biochemical assays 
Blood samples were collected from all the control and experimental animals, by retro-orbital 
puncture, before surgery, 1 month and 3 months post implantation. For blood cell count, 
blood samples were collected in K3-EDTA tubes and routine analysis of blood samples was 
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done in a Tulip CounCell23 automatic blood analyser (The Tulip Group, India). Serum 
samples were obtained by centrifuging the collected blood at 3,000 RPM for 10 mins at 4ºC 
and stored in -80ºC until use. Serum biochemical tests were done in Tulip CORALAB-3000 
serum analyser (The Tulip Group, India). 
 
3.6.3 Radiology and DXA 
X-Ray Radiography was performed to measure the Bone Mineral Content (BMC) and Bone 
Mineral Density (BMD), around the implant area, of live experimental and control animals, 
1, 2 and 3 months after implantation by Dual Energy X-Ray Absorbtiometry (DXA) in a 
Hologic Discovery QDR® Series (Bedford, MA, USA) to follow up the healing process after 
the surgery and before removal of the implanted femur. The mineral concentration and 
density of the region was calculated using the QDR software provided by the instrument 
suppliers.   
 
3.6.4 Anaesthesia, surgery and euthanasia 
Animal surgery was performed in an operating room. Rabbits were anesthetised by 
intramuscular local administration of a combination of ketamine hydrochloride (150 mg/kg 
body weight) and xylazine hydrochloride (30 mg/kg body weight) (Troy Laboratories, 
Glendenning, NSW, Australia) in a volume of 0.5 ml/kg body weight, prior to surgery. The 
hair in the thigh region was removed and the surgery area, located at the tibial end of the left 
femur, was disinfected with Povidone iodine solution. After exposing the dorsal side at the 
distal end of the left femur bone (about 1 cm above the knee joint), a small cavity of 
approximately 2.5 mm diameter and 4.2 mm depth was drilled through the cortical region 
using a paediatric bone driller (Asian Surgicals, Hyderabad, India). A sterile implant was 
placed in the cavity and the implant was covered with the adjoining muscle tissue, which was 
sutured using absorbable suture material (Ethicon, Somerville, NJ, USA), and the skin layer 
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surrounding the muscular region was sutured by interrupted suturing with non-absorbable silk 
thread and a 3–0 needle (Ethicon, Somerville, NJ, USA). In the control group, no implant 
piece was placed into the drilled cavity and the drilled hole was left bare. After surgery the 
surgical area was applied with Betadine ointment (5%, w/w Providone iodine, Win-Medicare, 
New Delhi, India) and 0.5 ml Meloxicam (Intas Pharma, Ahmedabad, India) was injected 
subcutaneously to prevent infection and inflammation in the surgical area; Lorexane ointment 
was applied locally until the wound healed. All animals were kept under close observation 
until the end of the experimental period during which ad libitum access to food and water 
(sterile) without antibiotics was available to the animals. They were also allowed to move 
freely within the cage without any support. All the animals were kept under close observation 
for 3 months, during which time no mortality or morbidity in the animals was observed. After 
the period of observation for 1 and 3 months, the animals were euthanised using carbon 
dioxide inhalation for biochemical, radiological, and histological analyses. 
 
3.7 Bone Processing and Sectioning 
Immediately after excision each bone specimen (approximately 1 cm3) was fixed in 35 ml of 
10% neutral buffered formalin (NBF) prepared in phosphate buffered saline (PBS) (pH 7.2), 
for a period of 48 h at 4 °C under constant stirring. After fixation, the specimens were 
dehydrated in increasing grades of isopropyl alcohol (IPA) (70%, 80%, 95%, and 100%), 
each for 24 h and finally cleared with two cycles of xylene (100%) treatment, each for 24 h. 
The samples were then processed for embedding. 
 
3.7.1 MMA embedding 
The embedding of bone samples was carried out in two stages: (a) infiltration and (b) 
polymerisation. Each NBF-fixed bone sample was infiltrated by successive treatments with 
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35 mL solutions of three types of methyl methacrylate (MMA) (Merck, Fairlawn, NJ, USA) – 
MMA I (60% MMA, 35% butyl-methyl-methacrylate (BMA) and 5% methyl benzoate mixed 
with 1.2 ml of polyethylene glycol 400), MMA II (MMA I + 0.4% (w/v) benzoyl peroxide) 
and MMA III (MMA I + 0.8% (w/v) benzoyl peroxide). Each infiltration step was carried out 
at 4 °C for 3 days under constant stirring for efficient infiltration. The bone samples were 
then placed in 5 ml glass vials (Borosil Glass Works, Ahmedabad, India) containing a 3 ml 
bed that had been previously prepared by mixing MMA III + 0.6% (v/v) N, N dimethyl-p-
toluidine and polymerised at 4 °C for 24 h in the presence of nitrogen gas. The bone 
specimens were oriented so that the implant surface was at right angle to the axis of the 
implant in order to get sagittal sections of the implant area. The embedding polymer (MMA 
III + 0.4% N, N dimethyl-p-toluidine, v/v) was poured on top of the bone specimen up to the 
neck of the vial and capped immediately without any exposure to air. Complete 
polymerisation of the resin was carried out in the absence of UV exposure by carefully 
placing the glass vials in a −20 °C freezer (LG, South Korea) for 48–72 h without disturbing 
the orientation of the specimen. The low temperature polymerisation reduces the heat 
generated by the polymerisation reaction. Finally the polymerised blocks with the bone 
specimens were removed from the vials by breaking the glass and stored at room temperature 
till further use. 
 
3.7.2 Bone sectioning 
The embedded bone sections of 10 μm thickness were prepared using a rotatory saw 
microtome (Leica SP1600, Leica Biosystems, Wetzlar, Germany). For classical stains, the 
sections were mounted on glass slides (Blue Star, Polar Industrial Corporation, Mumbai, 
India) freshly coated with Mayer’s egg albumin (egg white:glycerol; 1:1) freshly diluted in 
order to achieve good adherence of the sections to the slides. For histochemical and 
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immunohistochemical analysis the sections were mounted on a freshly prepared 0.1% (w/v) 
poly L-lysine (diluted in distilled water) (Sigma–Aldrich, St. Louis, MO, USA) coated glass 
slides. Sections collected on poly-L-lysine coated slides were kept at 37 °C for 1 h to 
facilitate good adherence of the sections to the slides. The mounted sections were stored at 
room temperature until further use. 
 
3.7.3 Deplasticisation 
Deplasticisation of the bone sections were carried out using 2-methoxy-ethyl-actetate 
(Sigma–Aldrich, St. Louis, MO, USA) three times for 20 min each and finally washed in 
distilled water (DW). Deplasticised sections were treated with different staining protocols to 
visualise the cells and ECM of the newly formed tissue. 
 
3.8 Histology 
3.8.1 Hematoxylin and Eosin 
After deplasticizsation, sections on albumin-coated slides were washed twice in deionised 
water each for 10 min, and then stained with hematoxylin for 6 min. This was followed by 
washing with tap water for 10 min or until the tissue colour turned bluish followed by eosin 
staining for 45 s. Stained sections were dehydrated using 95% IPA three times for 2 min each 
and with 100% IPA for 2 min. The sections were mounted using Permount® (Fisher 
Scientific, Waltham, MA, USA). 
 
3.8.2 Tartrate Resistant Acid Phosphatase (TRAP) assay 
Sections on poly-L-lysine coated slides were incubated in acetate buffer (pH 5.0) for 20 min 
at room temperature and then in acid phosphatase–substrate solution containing naphthol AS-
MX phosphate (Sigma–Aldrich, St. Louis, MO, USA) and Fast Red (Sigma–Aldrich) 
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dissolved in acetate buffer at 37 °C for 1–4 h. Incubation time for every slide was optimised 
by checking the bright red coloration of osteoclasts. The stained sections were washed in 
deionised water and mounted in Kaiser’s glycerol gelatine (Merck, Darmstadt, Germany). 
 
3.8.3 Masson Trichrome 
Staining was done on sections attached to albumin-coated slides. The sections were stained 
with Weigert’s hematoxylin for 6 min followed by washing in 1% acid–alcohol (7–8 dips) 
followed by running tap water wash for 10 min. The sections were then stained with Biebrich 
scarlet–acid fuschin solution for 2 min, rinsed in three changes of deionised water and placed 
in 5% phosphotungstic acid for 15 min followed by two changes of deionised water. Finally, 
the sections were stained in light green solution for 7 min, rinsed twice with deionised water 
and treated with 1% acetic acid solution for 3–5 min. The stained sections were dehydrated 
using 95% and 100% IPA and two changes of xylene each for 5 min and mounted with 
Permount® (Fisher Scientific, Waltham, MA, USA). 
 
3.8.4 Sirius Red Staining 
After deplasticisation, the bone sections were placed in 2% KOH for a period of 30 min for 
maceration. The sections were then transferred to 1.5% Alizarin Red solution (pH 7.4) until 
the sections turned red under the microscope. Excess stain was removed by 1%-2% KOH. 
The sections were washed in DW and mounted using Kaiser’s glycerol gelatin (Merck, 
Darmstadt, Germany). 
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3.9 Immuno-Histochemistry 
3.9.1 Collagen type-I and Vimentin 
Col-I immunostaining was performed to study the ECM distribution laid by osteoblasts in the 
peri-implant site. The sections were placed on poly-l-lysine coated slides, and deplasticised. 
Sections were then rehydrated by washing twice in Tris buffered saline (TBS) for 5 min. This 
was followed by antigen retrieval step, using proteinase K solution, at 37°C for 20–30 min. 
Blocking of endogenous peroxidase activity was done by incubating them in 3% hydrogen 
peroxide for 30 min at room temperature prior to staining procedure. After this, the sections 
were washed twice in TBS and incubated in 3% bovine serum albumin (BSA) for 30 min to 
prevent non-specific binding of antibodies. For antibody staining, the sections were divided 
into two groups- (a) one group was used for incubation with primary anti-collagen I and anti-
vimentin antibodies; (b) the other was used as a control, where no incubation of first antibody 
was done, but the sections were immersed in TBS. Sections in the first group were incubated 
with primary antibody for monoclonal IgG1 anti-Col antibody (Sigma–Aldrich, St. Louis, 
MO, USA) and monoclonal IgG1 anti-vimentin antibody made in mice (Sigma–Aldrich, St. 
Louis, MO, USA) at 1:500 dilutions in room temperature for 45 min and 1 h, respectively, 
and washed three times in TBS for 5 min each. Sections from both groups (experimental and 
control) were further incubated with horseradish peroxidase (HRP) conjugated goat anti-
mouse antibody (Sigma–Aldrich, St. Louis, MO, USA) for 30 min at room temperature and 
then washed in TBS three times each for 5 min. 3, 3-Diamino-benzidine (DAB) (Roche 
Diagnostics, Indianapolis, IN, USA) was used as the substrate (according to the 
manufacturers’ instructions) for visualisation of peroxidase enzyme activity on the sections. 
Incubation reaction was done until the section turned brown in colour. The sections were 
carefully observed under the microscope to prevent over-staining, washed in DW and 
mounted using  
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3.10 Microscopy 
Images of the stained sections were taken using Zeiss Axioplan 200M microscope (Carl 
Zeiss, Oberkochen, Germany) fitted with an Axiocam Mrc digital camera and the images 
were processed via the Axiovision® Version 5 software provided by the instrument supplier. 
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Chapter 4 
Effect of Zirconium, Calcium and Strontium Contents on 
Implant-Induced osseointegration 
 
4.1 Introduction 
Because of their varied attractive properties, many metals and their alloys have been 
considered as biomedical implants. The idea of biodegradable alloys initiated with the 
necessity for secondary surgery for removal of the implanted material and their unsuitability 
in load bearing applications. A number of Mg based alloys, prepared with alloying elements 
from the same group of the periodic table, have been reported for dental replacements and 
orthopaedic applications [8, 13, 14]. Mg enriched materials have been studied as oral 
implants [149] and as filler materials in extracted sockets [150] in animal models to evaluate 
their influence in restoration or replacement of dental abutments. The application of alloys 
and implant materials, placed into the extracted sockets immediately after tooth extraction 
have reported beneficial effects [151, 152]. However, such techniques could not demonstrate 
their capability of maintaining the bony crest in its original shape for long periods of time 
because of their high corrosion and degradation in vivo. The biological and corrosion 
properties of Mg alloys have been studied in detail [153-156], and their application as 
orthopaedic implants has been widely accepted due to (a) their characteristic biodegradability 
and biocompatibility in vivo [153-155], and (b) their established role in bone formation e.g. 
ability to influence mineral metabolism in the bone matrix and promotion of osteoblast 
specific cell signalling in vivo, without causing inflammatory reactions in the neighbouring 
tissues [36]. In addition, mechanical properties such as elastic modulus and compressive yield 
strength of many Mg based alloys closely match with that of natural bone tissue [157].  
Chapter 4. Effect of Zirconium, Calcium and Strontium Contents on Implant-induced 
Osseointegration 
 
52 
 
In spite of the above mentioned advantages, Mg-based alloys present some significant 
challenges in their usage as bio-implants, for example (a) many Mg containing implants 
corrode quickly at the physiological pH range of 7.4-7.6 [8, 158], and (b) they release 
hydrogen gas around the implant area leading to loss of mechanical integrity even before the 
tissue is healed and the new bone is mineralised [159, 160]. The performance of Mg based 
alloys is also affected because of the instability of the protective hydroxide film on their 
surface that dissolves in aqueous environments [161]. Using appropriate combinations of 
alloying elements with the base alloy can significantly reduce these defects of Mg based 
alloys. An ideal alloying element composition would stabilise the hydroxide film on the 
surface, increase their corrosion resistance and mechanical properties and thus improve their 
biocompatibility and bio-efficacy. In this direction, alloys of Mg with Sr, rare earth elements, 
Ca, aluminium (Al), trace levels of manganese (Mn), zinc (Zn), Zr, and silicon (Si) have been 
used to make new generations of orthopaedic implants [162-169]. An important factor while 
designing these bioactive implant surfaces is the biological response of cells to the alloys 
which ultimately correlates with the success of implants in the host tissue. The idealised 
biological efficacy of an implant would be where the implant material gets totally 
amalgamated with the newly formed osseous tissue and thereafter it disintegrates into the 
blood stream without causing damage to the vital organs or losing its functionality [170].  
The main aim of the present study was to check the stability and in vivo cellular response to 
Mg alloyed with Zr, Sr and Ca and to evaluate the influence of these divalent cations on the 
in vivo compatibility of these alloys. We hypothesise that inclusion of Sr in Mg alloys can 
change their surface properties and can control the potential of these alloys to interact with 
the osteoblast cells. This can lead to osteogenesis, osteoinduction and osseointegration 
leading to ECM formation around them upon implantation. The addition of Zr, Sr and Ca to 
Mg can influence their degradability and biocompatibility in different ways. Taking these 
Chapter 4. Effect of Zirconium, Calcium and Strontium Contents on Implant-induced 
Osseointegration 
 
53 
 
facts into consideration, we report the effect of Mg alloys on the in vivo degradation, bone 
forming ability and mineralisation in addition to the impact of these alloys on the BMC and 
BMD of the implanted animals. 
 
4.2 Results 
4.2.1 Mechanical and surface properties 
4.2.1.1 Alloy composition and physicochemical characterisation 
The detailed alloy compositions of the four substrates are given in Table 4.1.  
 
As can be seen the substrates were almost free of contaminants such as Al, Fe, Mn and Si and 
the relative contents of base (Mg) and alloying (Zr, Sr and Ca) metals were as per the desired 
values in every substrate. The XRD data (Fig 4.1) showed that all alloys contained a 
dominant and primary α-Mg phase. In addition to this, in Mg-2Zr-5Sr and Mg-Zr-2Sr alloys, 
a strong and intermediate peak for the Mg17Sr2 intermetallic phase could be seen; this peak 
was absent in the other two alloys. Intermetallic Mg-Zr peaks were absent in alloys – this 
could be attributed to their low solubility in the presence of Mg and distribution of α-Zr 
particles in Mg matrix, as has been explained by others [172]. Almost all the alloys exhibited 
good mechanical strength that matched the properties of normal bone tissue, making these 
Alloy Chemical composition (wt%) 
 Zr Sr Ca Al Si Fe Mn Mg 
Mg-5Zr 4.88 - - 0.02 0.01 0.01 0.01 Balance 
Mg-5Zr-Ca 4.41 - 0.91 - - 0.01 0.01 Balance 
Mg-2Zr-5Sr 1.89 4.8 - 0.03 0.02 0.01 0.01 Balance 
Mg-Zr-2Sr 0.92 1.82 - 0.04 0.02 0.02 0.01 Balance 
Table 4.1.  Nominal composition of Mg-based alloys [171]. 
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alloys suitable and potential candidates for temporary implant applications. The compressive 
strengths of Mg-5Zr, Mg-5Zr-Ca, Mg-2Zr-5Sr and Mg-Zr-2Sr alloys were estimated to be 
237.8, 255.7, 209.7 and 242.9 MPa respectively, which was within the range of the 
compressive strength of normal cortical bone (164-240 MPa) [158], except Mg-5Zr-Ca. As 
can be seen, addition of Ca to the Mg-Zr base alloy in Mg-5Zr-Ca, made it stiffer and more 
inflexible than the other three alloys. Based upon the compressive strengths and the 
composition of the alloys we decided to compare the bone inducing activity of Mg-5Zr-Ca 
vs. Mg-5Zr implants and Mg-2Zr-5Sr vs. Mg-Zr-2Sr implants. The first grouping was to 
evaluate the role of Ca and the second for evaluating the combined roles of Zr and Sr in the 
alloys. 
 
 
 
Figure 4.1. X-ray diffraction spectra of four Mg alloys. 
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4.2.1.2 Surface morphology and in vitro hydrogen gas release 
The SEM images of the alloys before incubation (Fig 4.2) in the culture media showed rough 
surfaces, with scattered distribution of particles having a floral arrangement. After incubation 
in culture media (Fig 4.3), we observed the appearance of cracks, pits and more roughened 
edges on all surfaces that could be biologically advantageous for the implants because such 
surface topographies can accelerate the osteoblast adhesion [172]. None of the alloys showed 
any indication of peri-implant gas bubble formation or its shadows up to three months. It is 
however possible that small amount of H2 gas was generated around the implant area within 
the first few days after implantation. This release of H2 gas was considered within tolerable 
limits and therefore H2 evolution from the implants was of little concern in our study. 
Figure 4.2. Scanning electron micrographs of Mg alloys before incubation in the culture media
[171].  
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4.2.1.3 Surface energy 
Table 4.2, fig 4.4 and fig 4.5 respectively shows the calculated free surface energy values and 
shapes of individual drops, and the left and right contact angles of all the alloys. Mean 
contact angles of the alloys were between of 23°-75° and the corresponding surface energies 
were in the range of 40-70 μJ/mm2 as shown in Table 4.2. Based on this we concluded that 
the surface energies of the alloys were in the following order - Mg-5Zr-Ca>Mg-5Zr>Mg-2Zr-
5Sr>Mg-Zr-2Sr. It is known that substrates with low surface energies are more hydrophobic 
than surfaces with high surface energies [174]. Therefore in our study, since Mg-Zr-2Sr 
showed the least surface energy and Mg-5Zr-Ca the most, Mg-Zr-2Sr was considered as most 
hydrophobic and Mg-5Zr-Ca as most hydrophilic. 
 
Figure 4.3. Scanning electron micrographs of Mg alloys after incubation in the culture media 
for 7 days [171]. 
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Alloy Liquid Left CA Right CA 
Mg-5Zr 
Water 25.25°r0.92 27.25°r0.49 
Glycerol 43.9°r1.27 46.65°r0.07 
Surface Energy (SE) 66.76 μJ/mm2 66.53 μJ/mm2 
Average SE 66.64r0.162 μJ/mm2 
Mg-5Zr-Ca 
Water 23.3°r0.71 24.3°r0.99 
Glycerol 45.7°r0.57 48.1°r1.98 
Surface Energy (SE) 68.27 μJ/mm2 69.40 μJ/mm2 
Average SE 68.83r0.79 μJ/mm2 
Mg-2Zr-5Sr 
Water 43.45°r0.64 41.65°r2.33 
Glycerol 53.65°r6.15 54.35°r3.04 
Surface Energy (SE) 55.60 μJ/mm2 57.17 μJ/mm2 
Average SE 56.38r1.11 μJ/mm2 
Mg-Zr-2Sr 
Water 63.85°r1.76 64.15°r1.91 
Glycerol 74.4°r2.68 73.55°r0.64 
Surface Energy (Se) 42.42 μJ/mm2 41.85 μJ/mm2 
Average SE 42.13r0.40 μJ/mm2 
Table 4.2. Mean left and right contact angle (CA) values and the respective surface energies 
(SE), with statistical standard deviations, of all the four Mg-based alloys. 
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Figure 4.4. Representative figures of contact angles of the four Mg alloys used for calculating 
surface energy. The contact angles (CA) were determined using water and measured within 
60 seconds of the droplet release from the syringe probe. 
Figure 4.5. Representative figures of contact angles of the four Mg alloys used for calculating 
surface energy. The contact angles (CA) were determined using glycerol and measured within 
60 seconds of the droplet release from the syringe probe. 
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4.2.2 In vivo bone formation 
4.2.2.1 Histological analysis of new bone formation 
The histological study of the implant induced bone properties at 12 weeks after implantation 
of the alloys gave us two-fold approach: on one hand the focus was on identifying the cell 
types within the newly induced bone tissue by doing HE and TRAP staining and on the other 
hand, features of the ECM of new bone by Col immunostaining and MT staining was 
depicted. HE staining showed no significant features of local inflammatory responses around 
the implants but the fibrous encapsulation of the Mg-5Zr and Mg-5Zr-Ca implant induced 
new bone (NB) indicated inflammatory response towards these implants (Fig 4.6).  
HE staining of the Mg-5Zr and Mg-5Zr-Ca induced bones also showed a non-uniform bone 
formation pattern that was rich in fibroblast like cells and an ECM that was filled with 
remnants of degraded alloy particles. These features of Mg-5Zr and Mg-5Zr-Ca implant 
induced bones were indicative of “distance osteogenesis” behaviour. In contrast Mg-2Zr-5Sr 
Figure 4.6. Hematoxylin and eosin stained bone sections (100×) of Mg alloys 3 months post-
implantation. The dots represent the implant–bone interface [171]. 
Chapter 4. Effect of Zirconium, Calcium and Strontium Contents on Implant-induced 
Osseointegration 
 
60 
 
& Mg-Zr-2Sr implant induced bones showed firm adhesion of the new tissue to the implant 
surface and a uniform osteoblast rich bone tissue, which represented the features of “contact 
osteogenesis”.  
TRAP staining of the peri-implant site showed a significantly higher number of osteoclasts in 
the Mg-2Zr-5Sr and Mg-Zr-2Sr induced bones as compared to Mg-5Zr and Mg-5Zr-Ca (Fig 
4.7), indicating more appropriate bone remodelling behaviour in the former. We could also 
notice the complete degradation of the Mg-2Zr-5Sr and Mg-Zr-2Sr implant materials, which 
could be responsible for the activation of osteoclasts. Between the Mg-2Zr-5Sr and Mg-Zr-
2Sr implants the total number of TRAP-positive cells was more in the Mg-2Zr-5Sr induced 
bones than in Mg-Zr-2Sr induced bones. The poor degradation of the Mg-5Zr and Mg-5Zr-Ca 
implants even after 12 weeks indicated their lesser osteoclast inducing capacity. 
Figure 4.7. Tartrate-resistant acid phosphatase staining of bone sections (100×) 3 months 
post-implantation. The red coloured cells represent osteoclasts at the peri-implant interface.
The dots represent the implant–bone interface. Imp, implant site; OC, osteoclasts [171]. 
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4.2.2.2 Immuno-histochemical analysis of newly formed bone 
A positive Col immunostaining could be seen in the ECMs of all the new induced peri-
implant bones but its levels were higher in Mg-2Zr-5Sr and Mg-Zr-2Sr induced bones (Fig 
4.8). Collagen type-I is one of the most abundant proteins of the mineralised bone matrix and 
it is a marker of early osteoblast differentiation [138]. It is synthesised in the osteoblasts and 
its secretion in the matrix indicates formation of an osteoid matrix.  
 
MT staining (Fig 4.9) was used to differentiate the unmineralised osteoids (red staining) from 
the mineralised ECM (blue staining) of mature bone tissue in the implant area. The bone 
response around the implants Mg-5Zr and Mg-5Zr-Ca were separated by a gap interface rich 
in fibrous tissue. The thickness of the fibrous tissue enclosing the implant Mg-5Zr is 135 μm  
Figure 4.8. Immunostaining of implanted bone sections (100×) by col-I, 3 months post-
implantation. Panels show osteoblasts lining the newly formed bone. The osteoblasts 
occupied significantly higher bone surface near the implant site in Mg-2Zr-5Sr and Mg-Zr-
2Sr. The dots represent the implant–bone interface [171]. 
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and that of Mg-5Zr-Ca is 176 μm. The cellular details of the dense fibrous envelope formed  
is well depicted in the MT stained sections where the well-structured collagen fibres are 
stained blue-green in colour and the cell nuclei in red. The peri-implant site of these implants 
showed superior bone contact after 3 months of healing period as depicted in Fig 4.9. These 
images are depictive of mature woven bone that distinguishes between osteoblasts and 
fibroblast mineralisation. Implant Mg-Zr-2Sr represented prominent osteogenic activity with 
mature woven trabecular bone formation after 3 months with implant site filled with spongy 
bone and no degradable particles illustrating uniform disintegration of the implant. The newly 
formed bone was completely mineralised in Mg-Zr-2Sr while Mg-Zr-2Sr showed 
unmineralised bone (osteoid) in red when stained with MT. The osteoblasts lining the 
trabecular surface were pre-dominant around the peri-implant interface of the implants Mg-
2Zr-5Sr and Mg-Zr-2Sr as shown by MT stained images. 
Figure 4.9. Masson’s Trichrome stained sections (100×) of magnesium alloys 3 months post-
implantation. The dots represent the implant bone interface [171]. 
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4.2.2.3 Radiography and bone density measurements 
The mean BMC and BMD values of the implant induced bones (three animals for each alloy) 
and three control animals recorded at monthly intervals for three months are shown in Figs 
4.10A and 4.10B, respectively. BMC values for control animals did not show any increase 
with time whereas in all implant-containing bones, the values increased significantly by the 
third month when for Mg-2Zr-5Sr and Mg-Zr-2Sr implants they were higher than Mg-5Zr 
and Mg-5Zr-Ca. Interestingly, BMD values for all the implants remained more or less similar 
to control values showing no significant change. This difference in the variation of BMC and 
BMD values implies that after 3 months the total area (or volume) of healed bone in Mg-2Zr-
5Sr and Mg-Zr-2Sr implant bearing wounds was bigger than the healed areas of control or 
Mg-Zr-2Sr implant bearing bones. Further, this data reflects the osteoinductive property of 
the Mg alloys. Hydrogen evolution rates were calculated based on immersion tests performed 
by incubating the substrates in SBF and Fig 4.10C shows the data for all the four alloys. As 
expected, all the substrates exhibited release of hydrogen gas upon immersion in SBF, which 
was in direct correlation with their immersion time. Mg-5Zr-Ca showed maximum hydrogen 
evolution at 72 hrs indicating that it had corroded and dissolved entirely in SBF by that time. 
In contrast, the Sr containing alloys showed a more optimized hydrogen evolution and 
degradation behaviour in relation to those alloys that did not contain Sr. A representative X-
ray image of implanted area for the Mg-Zr-2Sr implant is shown in Fig 4.10D. We also 
noticed that after three months of implantation, the implanted pellets of the alloy had 
degraded and their edges had become too fuzzy to be recognised. The degradation levels of 
the implants were variable from alloy to alloy which became more evident in the histological 
analysis. 
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Figure 4.10.  Physiological, physicochemical, and anatomical effects of the four Mg alloys 
used for implantation. Panels A and B show BMC and BMD, respectively, of the implanted 
animals after 1, 2, and 3 months post-implantation for control and experimental animals. Data 
shown are mean values taken from three experimental animals in each time point. Panel C 
shows hydrogen evolution rates of magnesium alloys upon incubation in simulated body fluid 
for 7 days. Panel D shows X-ray radiograph of a representative implanted live animal (Mg-
Zr-2Sr) after 3 months implantation [171]. 
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4.2.2.4 Blood cell counts and serum biochemical measurements 
Total blood-cell count and serum biochemical analysis of the rabbits performed 3 months 
after implantation gave the information on inflammation, liver and kidney functions. The 
blood examination results are listed in Table 4.3. The rabbits implanted with Mg-5Zr and 
Mg-2Zr-5Sr showed slight increase in lymphocytes (LYM), hematocrit (HCT), mean 
corpuscular volume (MCV) and mean cell hemoglobin concentration (MCHC). An increase 
in platelet (PLT) count was found in Mg-Zr-2Sr. However, these elevations do not indicate 
any kind of disturbances in the blood count. All the animals were in good physical condition 
and free from any kind of diseases within the prescribed implant period. Furthermore, it did 
not indicate any kind of systemic inflammatory reactions. Serum biochemical values of urea, 
uric acid, creatinine, serum glutamic–oxaloacetic transaminase (SGOT), serum glutamic 
pyruvic transaminase (SGPT), alkaline phosphatase (ALP), total protein, magnesium, 
calcium and chloride from rabbits implanted with Mg alloys are listed in Table 4.4. The 
kidney-related parameters include urea, uric acid and creatinine levels in the serum. Liver 
functions could be monitored by checking SGOT, SGPT, ALP and total protein whereas 
normal body electrolytes were monitored, by checking Mg, Ca and Cl levels in the serum. All 
the alloys showed elevated values for urea as compared to the control, except Mg-Zr-2Sr. 
This could indicate that the degradation of Mg alloys caused a limited effect on kidney 
functions. Serum ALP and Ca showed elevated values beyond the normal recommended 
levels. All the other serum parameters were within the normal range. This suggests that by 3 
months, the liver function was not affected by degradation of these alloys. Balance of 
electrolytes in the body is necessary for normal functions of cells and organs. The unaltered 
electrolyte balance signifies that the in vivo degradation of Mg alloys did not cause any 
disturbance to the normal electrolyte levels of the implanted subjects. 
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Sl. No. Agent Unit Control Mg-5Zr Mg-5Zr-Ca Mg-2Zr-5Sr Mg-Zr-2Sr  Range 
1 WBC X103/mL 9.03 ± 2.07 7.07 ± 0.38 6.16 ± 2.50 7.63 ± 2.47 10.52 ± 1.69 5.1 - 9.7 
2 LYM  % 77.15 ± 16.00 77.03 ± 1.39 27.25 ± 1.34 87.20 ± 5.49 57.62 ± 17.05 39 - 68 
3 RBC X106/mL 5.92 ± 0.28 6.50 ± 0.16 5.52 ± 0.35 6.03 ± 0.46 4.76 ± 0.75 5.3 - 6.8 
4 HGB  g/dL 12.98 ± 1.15 14.27 ± 0.46 12.18 ± 0.69 10.80 ± 2.19 11.18 ± 2.56 9.8 – 14.0 
5 HCT  % 40.38 ± 0.54 50.37 ± 1.33 35 ± 3.25 45.53 ± 1.42 35.20 ± 2.02 34 - 43 
6 MCV fL 68.43 ± 4.20 77.53 ± 0.15 63.45 ± 1.87 75.77 ± 3.63 75.21 ± 10.49 60 - 69 
7 MCH  pg 21.88 ± 0.87 21.90 ± 1.05 22.01 ± 0.16 18.23 ± 3.74 23.27 ± 2.17 20 - 23 
8 MCHC g/dL 32.15 ± 3.28 28.30 ± 1.45 34.80 ± 1.27 24.07 ± 4.39 31.54 ± 5.97 31 - 35 
9 PLT  X103/mL 418.67 ± 237 472.33 ± 160 1219.50 ± 104 479.00 ± 224 1085.28 ± 316 158 - 650 
Table 4.3. Blood cell count of control and experimental animals 3 months after implantation. WBC- White Blood Cells; LYM- Lymphocytes; 
RBC- Red Blood Cells; HGB- Hemoglobin; HCT- Hematocrit; MCV- Mean Corpuscular Volume; MCH- Mean Corpuscular Hemoblobin; 
MCHC- Mean Corpuscular Hemoblobin Concentration; PLT- Platelet. 
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Parameters Control Mg-5Zr Mg-5Zr-Ca Mg-2Zr-5Sr Mg-Zr-2Sr Range 
Liver functions            
Urea (mg/dL) 24.91±2.186 35.68±8.426 49.51±9.736 22.83±4.173 25.17±1.914 5.00-25.00  
Uric acid (mg/dL) 0.76±0.016 0.82±0.185 0.69±0.084 1.59±0.634 1.13±0.559 1.0-4.3  
Creatinine (mg/dL) 1.03±0.046 1.23±0.195 1.39±0.126 0.76±0.062 1.27±0.369 0.5-2.6  
Kidney functions            
SGOT (U/L) 22.48±2.410 19.18±2.333 61.50±10.136 31.29±3.358 19.92±9.581 10.0-86.0 
SGPT (U/L) 28.20±2.870 37.78±1.333 65.42±16.494 37.57±10.667 43.79±2.822 20.0-120.0  
ALP (U/L) 116.02±9.770 125.80±2.921 105.13±27.555 89.62±1.324 105.81±0.584 25.0-65.0  
Total protein (g/dL) 4.30±0.470 6.52±3.344 3.40±0.301 5.16±0.026 8.42±0.888 5.0-7.5 
Electrolytes            
Magnesium (mmol/L) 2.50±0.138 2.36±0.534 2.21±0.385 2.61±0.019 2.51±0.387 2.0-5.4  
Calcium (mg/dL) 15.95±0.759 17.95±0.002 18.69±1.297 14.85±2.589 16.75±0.059 5.6-12.1  
Chloride (mmol/L) 95.08±12.371 95.61±22.144 91.65±4.134 117.48±4.614 105.73±2.681 92.0-120.0  
Table 4.4. Values of serum biochemical parameters of control and experimental animals after 3 months implantation. SGOT - Serum 
glutamic oxaloacetic transaminase; SGPT - Serum glutamic pyruvate transaminase; ALP - Alkaline phosphatase. 
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4.3 Discussion  
4.3.1 Analysis of alloying and matrix properties 
Implant stability plays a vital role in determining the biological efficacy of endosseous 
prostheses. The material stability criteria become even more critical in the case of 
biodegradable implants because it is essential for the implant to induce sufficient and quality 
bone tissue around itself before its properties are diminished and the implant itself 
decomposes. The surfaces of metal-based implants are highly reactive in biological systems 
and numbers of reactions are observed at the implant-bone interface that can determine the 
stability of the implant and quality of osseous regeneration. Some of the important factors 
that facilitate optimum osseointegration include – physicochemical properties of the material 
surface, bioactivity of alloying elements, rate and kinetics of implant degradation and the 
type of interaction between implant material and surrounding tissues. 
 
4.3.2 Role of individual alloying elements in implant stability 
Our work has mainly focused in studying the stability of four different Mg alloys containing 
different quantities of Zr, Sr and Ca, and in correlating the surface energy of each alloy to its 
capacity for osteoinduction and integration at the implant site in rabbit femur bones. Based on 
our results we have demonstrated that Zr-Sr alloys (Mg-2Zr-5Sr and Mg-Zr-2Sr) are superior 
biomaterials for orthopaedic applications than alloys that contain only Zr or a combination of 
Zr and Ca.  It can be seen from the XRD data in Fig 4.1 that there is a formation of Mg17Sr2 
intermediate phase in Sr containing alloys (Mg-2Zr-5Sr & Mg-Zr-2Sr). Mg17Sr2 is reported to  
be the most Mg-rich stable compound in the Mg-Sr system [162], which can improve the 
corrosion resistance of Mg based alloys. Inclusion of Zr in Mg alloys acts as a grain-refining 
agent, which causes strengthening of the alloy by formation of α-Zr phases and grain 
boundary strengthening [175]. In our study Ca or only Zr containing alloys (Mg-5Zr and Mg-
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5Zr-Ca) were unstable and upon degradation in vivo they showed a lot of residual alloy 
material at the implant site (Figs 4.6 and 4.7). This has not been reported earlier because the 
stability of Ca containing Mg alloys has been studied only in the absence of Zr [167, 176-
178] and Mg alloys containing only Zr have not been reported so far.  
 
4.3.3 Role of individual alloying elements in bone formation  
The elemental constitution of the alloying metals also affects the properties of newly induced 
bone as several charged groups (O, OH- etc) on the alloy surface contribute to the overall 
electronegativity of the implant material [179]. In recent report using Ti based implants it has 
been shown in addition to the electronegativity of the implant surface that several other 
factors can also influence the osteoinduction process in vivo [180]. The advantages and 
limitations of individual alloying metals have also been described in our previous report 
[181] where we have shown that alloying processes improved the mechanical strength of 
implant materials and made their properties similar to those of the bone tissue. Based upon 
these criteria we can conclude from our results that Mg-5Zr-Ca implant, which showed high 
compressive strength, was not suitable for osseointegration whereas Mg-2Zr-5Sr and Mg-Zr-
2Sr implants that contained Sr tend to resemble more to natural bone in their properties due to 
decreased compressive strength.  
 
4.3.4 Analysis of cell and matrix properties in the new bone 
For assessment of bone formation in vivo the two most important properties of implant-
induced NB tissue are osteoinduction and osseointegration. We have evaluated these two 
processes by histological and immuno-histochemical staining of the peri-implant bone 
sections. 
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4.3.3.1 Proximity of new bone and implant surfaces 
In contact osteogenesis, the NB formation occurs on the surface of the implant itself. The 
osteoblasts secrete a collagen-rich bone matrix directly on the implant surface as they 
differentiate into osteocytes. In later stages the matrix is mineralised as calcified collagen and 
a matrix free area separate the old bone from the NB [182]. In distance osteogenesis, NB is 
formed over the old bone surface and the differentiating osteoblasts/osteocytes and the 
secreted matrix is all seen in close association with the surface of the old bone. Due to this 
pattern of cells and bone matrix, a space is generated between the NB and the implant 
surface, which gets occupied with dying or undifferentiated osteoblasts that are unable to 
migrate from the bone surface [182].  
As mentioned earlier Mg-2Zr-5Sr and Mg-Zr-2Sr alloys induced NB exhibited contact 
osteogenesis whereas Mg-5Zr and Mg-5Zr-Ca induced NB had distance osteogenesis 
properties, which are highlighted in the H&E staining patterns shown in Fig 4.6. In addition, 
the presence of differentiated osteoclasts, which is indicative of better bone resorption 
activity, in the Mg-2Zr-5Sr and Mg-Zr-2Sr induced bones (Fig 4.7) suggested that the quality 
of bone tissue around these implants was superior to the other bone types. In contrast we 
observed hyperactivity of osteoclasts in Mg-5Zr-Ca induced bones, which led to deformed 
and weaker bone tissue. 
 
4.3.3.2 Extent of bone mineralisation 
The facilitation of bone formation around the Mg-based implants is associated with the 
release of free Mg2+ ions during the biodegradation process, which can contribute to the 
enhanced activity of osteoblasts and a consequent increase in the quantity of ECM in the peri-
implant bone. In our study we analysed this activity by Col immunostaining and MT staining. 
Collagen type-I is an important marker of better quality osteogenesis [183] and we could 
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observe this in Mg-2Zr-5Sr and Mg-Zr-2Sr induced bones (Fig 4.8). The extent of 
mineralisation is shown by deep blue staining of MT and DXA results (Figs 4.10A & 4.10B). 
The blue stained sections distinguishes the mineralised and non-mineralised ECM. DXA 
measurements of BMC and BMD gave us the idea of bone growth and accumulation on and 
around the implanted site. From the DXA measurements, most of the component of bone 
accumulation that is associated with change in bone size is detected as bone mass and bone 
density. Our results gave good BMC and BMD for the implanted femur bones, which are in 
line with the results of histology and immuno-histochemical studies. 
Further, the impact of bone formation based on blood and serum biochemical analysis has 
been reported in this research. The elevated blood platelet numbers in Mg-Zr-2Sr in the third 
month (Table 4.3) indicates platelet activation, which can make cells aggregate and form a 
clot. Stable clot formation is required for secretion of biochemical components for 
osteoconduction [184]. 
 
4.3.5 Role of surface energy in in vivo biological studies 
The surface energy and wettability of the implant material is significant in determining cell-
biomaterial interactions and it significantly influences biological events at the sub-cellular 
and cellular level (eg., protein adsorption, cell attachment and spreading etc.) [185]. In our 
study, Mg-Zr-2Sr alloy exhibited lowest surface energy which could be attributed to lower 
weight percent of Zr and Sr (1 and 2wt% respectively) and hence more availability of free 
Mg2+ ions in the vicinity of this alloy. Further, lower surface energy levels of Sr containing 
Mg-2Zr-5Sr and Mg-Zr-2Sr alloys in comparison to Mg-5Zr and Mg-5Zr-Ca alloy surfaces 
signifies the role of Sr in controlling the surface energy levels of these alloys. Since Mg-2Zr-
5Sr and Mg-Zr-2Sr alloy-induced NB tissues exhibited “contact osteogenesis” properties, 
whereas Mg-5Zr and Mg-5Zr-Ca alloy-induced bone tissues showed “distance osteogenesis” 
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properties, it can be predicted that Sr containing Mg-Zr alloys with lower surface energy 
could induce better bone formation in vivo than high surface energy containing Sr deficient 
Mg-Zr alloys. 
 
4.3.6 Recommended strategies for material evaluation and significance of Sr levels in 
Mg-Zr implants 
The surface integrity of the alloys decides the rate and extent of bone formation, 
osseointegration and osteoconduction. In vivo evaluation becomes necessary to understand 
how the implant will perform in a physiological environment. Various physicochemical 
factors can play equally important roles in new bone induction [180] and hence no single 
property should be considered as the only criterion for selecting the implant material for 
orthopaedic applications. Our study highlights the importance of including Sr and excluding 
Ca in optimal combinations of Mg-Zr alloys to obtain good osteogenic outcome in rabbit 
bones. The clinical significance of our study undoubtedly lies in alloying Sr with Mg-Zr 
based biodegradable alloys and that 2wt% of Sr alloying in Mg-Zr system can improve the 
bone remodelling rate in vivo. Although we have used a total of 30 numbers of animals for 
the in vivo experiments, more detailed investigation on bone formation on the Mg-Zr-Sr/Ca 
implants would need a cohort of animal study before the implants can go for the clinical trial. 
Also, supplemental in vivo investigation on larger animal models is required to determine the 
efficacy of the Mg alloy system under more complex biological conditions. Nonetheless, Mg-
Zr alloys containing Sr as a complementary bivalent cation in optimum quantities can be used 
to promote efficient osseointegration for orthopaedic implant applications. 
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4.4 Summary 
We have studied a new class of biocompatible and biodegradable implants, composed of Mg 
as a base alloy and containing varying quantities of Zr, Sr and Ca. Some basic 
physicochemical properties of these alloys have been described earlier [181]. Here we have 
estimated the surface energy of the alloys by measuring the contact angle of polar solvents on 
the alloy surface, and correlated it with their bone forming capacity in the peri-implant area 
by histological and radiological evaluation. It was found through our physico-chemical 
investigations that inclusion of Sr into the Mg-Zr alloy increases both the corrosion resistance 
and stability of these alloys. Presence of Sr leads to formation of Mg17Sr2 intermediate phase 
that strengthens the alloy in Mg-rich system. The compressive strength of these alloys 
resemble more to the natural bone upon addition of Sr. Our results show that optimal contents 
of Zr and Sr increase the surface energy of the alloys and their capacity to simulate “contact 
osteogenesis” in the peri-implant area. The inclusion of Ca without Sr reduces the surface 
energy on the alloy surface and decreases its bone inducing activity. The osteogenesis, 
osteoinduction and osseointegration of Sr-containing alloys could be seen by mineral and 
trabecular bone formation on the implant surface.  Further, the DXA, blood and serum 
biochemical measurements prove that the bone growth and mineral accumulation on the 
implant surface is best for the Sr-containing alloy. The pattern of contact osteogenesis 
remained the same in both the Sr-containing Mg alloys. However, the higher concentration of 
Sr (5wt%) gave greater level of bone formation probably due to the presence of higher 
amount of secondary phase which could later grow uncontrollable as compared to the lower 
concentration (2wt%) as seen by histological and immuno-histochemical studies of these 
alloys. Through our physico-chemical, biochemical, histological and immuno-histochemical 
findings, we report that the presence of Sr gives Mg-Zr implants the property of contact 
osteogenesis. Although more detailed in vivo studies are required to confirm the superior 
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bone healing capacity of Sr, the present results indicate that Sr in Mg-based alloys notably 
increases early bone apposition in rabbit cancellous bones and that 2wt% Sr is the optimum 
concentration for Mg-Zr-Sr alloys to get the best osseointegration by influencing the surface 
energy of Mg-Zr alloys and their rate and extent of osseointegration. Further, it also helps in 
complete degradation of the implant within the specified period of surgery. In future, our 
results can guide the formulation of more efficient biodegradable alloys for orthopaedic 
applications.
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Chapter 5 
Collagen Type-I Leads to In Vivo Matrix Mineralisation 
and Secondary Stabilisation 
 
5.1 Introduction 
The success of orthopaedic implants depends entirely on the bone-implant interface. Implant 
osseointegration in the injured bone site decides the healing and regeneration within the bone 
tissue. The improper healing of wounded bones can result in bone fragility, calcification and 
abnormal bone quality and quantity. These differences in bone healing can be resolved by 
improving the implant stabilisation, which can be brought about with the help of 
biodegradable alloy implants. Since the discovery of magnesium (Mg) as a biodegradable 
material having combined mechanical, electrochemical, and biological features similar to 
natural bone, several reports have been published regarding Mg as orthopaedic implants [12, 
162, 171, 186]. It is present at high concentrations in cell and takes part in various cellular 
activities [5]. Mg is also a daily dietary requirement [187] and the dissolved Mg2+ ions are 
easily absorbed in our body [188]. Further, the mechanical properties of Mg are comparable 
with that of cancellous bone [8, 189]. However, the rapid dissolution in chloride-containing 
aqueous solutions [190] and low corrosion resistance of Mg and its alloys, leading to earlier 
degradation than the actual period of bone healing process still limit the use of Mg-based 
alloys as clinical implants.   
We have alloyed Mg with Zirconium (Zr) and Calcium (Ca) to improve its rate of 
osseointegration and implant stabilisation in a host tissue. Ca is reported to be a favourable 
non-toxic Mg alloying element and its addition can significantly enhance the mechanical 
properties and corrosion resistance of Mg alloys [92]. Zr has a powerful grain refining effect 
on Mg alloys, which improves the corrosion and mechanical properties of these alloys [181]. 
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Mg-Zr-Ca alloys are expected to be a promising candidate for use as an implant material. On 
the other hand, many reports have demonstrated that Collagen type-I (Col-I) imparts 
favourable effects on attachment, function and growth activities of osteoblast cell lines [138, 
191]. Besides Col-I, other extra cellular matrix (ECM) proteins such as fibronectin, through 
their Arginyl-Glycyl-Aspartic acid (RGD) peptide sequence, also influence osteoblast 
differentiation [192]. Incidentally, MC3T3-E1 cells have been reported to contain both the 
collagen binding integrin subunits α2β1, as well as fibronectin binding integrin subunit α5β1 
[193]. Col-I has also been presented to display osteoconductive properties in vivo [194, 195]. 
Although potentially beneficial in stimulating new bone formation, there is insufficient 
information about the cumulative effects of Col-I coating and Mg, Zr and Ca as alloying 
elements. Their performance in osseointegration and osteoconduction as in vivo implant 
would elucidate the capacity of Mg-based alloys to bridge the pre-prosthetic gaps that arise 
from the poor stability of alloy implants. Successful osseointegration depends on the primary 
stability of the alloy implant, which further influences the secondary stability. Primary 
stability is the stability shown by alloy material upon implantation. Once the reconstruction 
of bone tissue is initiated around the implanted material, the implant undergoes secondary 
stabilisation, characterised by its ability to promote osseointegration. This study describes a 
combinatorial approach of alloying Mg with Zr and Ca with the application of a bioactive 
coating of Col-I on the alloy implant surface. We have also reported in our previous work 
that the uncoated Ca-based Mg-Zr alloys corrode rapidly and hence are not bio-effective in 
osseointegration [171], but their physicochemical properties are enhanced when coated with 
Col-I thereby improving the bio-efficiency of these implants. Our findings demonstrate how 
Col-I coating Mg-Zr-Ca alloys give secondary stability to the implant by making them more 
osteoconductive over a period of 1 and 3 months implantation in rabbit femur and promote 
early and enhanced osseointegration. 
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5.2 Results 
5.2.1 Experimental animals 
The mean body weights of the implanted male New Zealand white rabbits, each for 1 and 3 
months is given in Table 5.1. 
 
 
 
 
 
5.2.2 Alloy microstructure and mechanical properties  
The XRD pattern (Fig. 5.1A & 5.1B) shows the phase constituents of Mg-based alloys. The 
α-Mg phases on the Mg-5Zr alloy surface could be seen with traces of unalloyed Zr. There 
are reports indicating that Ca addition leads to the formation of a thermal stable second phase 
Mg2Ca, which results in grain refinement of Mg casting [196, 197]. It is also noticeable that 
an intermetallic Mg2Ca phase coexists with α-Mg in the Mg-5Zr-Ca alloy. This is confirmed 
by microstructure images shown in Fig. 5.1C & 5.1D, showing intermetallic Mg2Ca 
precipitating along the primary α grain boundaries with a small amount of Ca phase. The 
grain size of Mg–5Zr-Ca is also seen to be much finer than that of Mg-5Zr. However, the 
microstructure of Mg–5Zr shows some unalloyed Zr particles (arrows) due to low solubility 
of Zr in Mg (only 3.8 wt%) [198]. The grain boundaries of Mg-5Zr-Ca are also rougher and 
broader than that of Mg-5Zr. The compressive strengths of Mg-5Zr and Mg-5Zr-Ca alloys 
were measured to be 237.8±10.1 and 255.7±7.2 MPa, respectively, making both the alloys 
behave close to the natural bone. Hydrogen evolution test was carried out to study the 
Alloy Before surgery 
(n=3) (Kg) 
After 1 Month 
(n=3) (Kg) 
After 3 Months 
(n=3) (Kg) 
Mg-5Zr 2.540±0.285 2.807±0.463 2.912±0.243 
Mg-5Zr-Ca 2.436±0.207 2.844±0.362 2.946±0.047 
Table 5.1. Measured body weights of experimental animals for Col-I coated Mg-5Zr and Mg-
5Zr-Ca alloy implants after 1 month and 3 months implantation. 3 animals were used for each 
alloy for each time period of implantation. 
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variation in corrosion rates with exposure time and the results are shown in Fig. 5.1E. Mg-
5Zr-Ca alloy displayed a high hydrogen production rate in SBF as compared to Mg–5Zr alloy 
and it degraded almost entirely after 72 h of immersion time. 
Figure 5.1. Panels A and B show the phases of Mg-5Zr and Mg-5Zr-Ca alloys, respectively, 
by X-Ray Diffraction. The α-Mg dominant phases and the unalloyed Mg(103)/Zr(103) phase 
could be seen on the surface of both the alloys. Secondary Mg2Ca phase could be seen on the 
surface of Mg-5Zr-Ca alloy. Panels C and D show the optical microstructures of Mg-5Zr and 
Mg-5Zr-Ca alloys, respectively, indicating unalloyed Zr particles along the grain boundaries. 
Panel E displays the hydrogen production rate of Mg-5Zr-Ca alloy showing higher amount of 
hydrogen release which increases with time.  
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5.2.3 Collagen coating properties  
The purity of the rat-tail tendon collagen prepared by us is shown in Fig. 5.2 (panels A and 
B). The coverage and integrity of the coating, as seen by FT-IR spectra, is demonstrated in 
Fig. 5.2, panel C. The SEM analysis of the exposed substrate-coating-interface indicated that 
the average coating thickness was about 1-1.5 μm (Fig. 5.3). 
 
 
 
Figure 5.2. Coomassie stained SDS-PAGE (Panel A) of Col-I extracted from rat tail on 8% 
resolving polyacrylamide gel. The gel extracts were then transferred to PVDF membrane for 
western blotting with mouse anti-collagen (Panel B). All three characteristic bands (α1, α2 
and β) that make a functional collagen were visible. Panel C shows the representative Fourier 
Transform-Infra Red (FT-IR) spectrum. The peaks for all the four amide groups 
corresponding to Col-I could be seen, including amide I region corresponding to the C=O 
absorption, amide II corresponding to CH2 and CH3 absorptions, amide III corresponding to 
C-N and N-H absorptions and amide IV corresponding to C-O and C-O-C absorptions of
carbohydrate moieties. The amide I region (1600-1700 cm-1) of the spectrum of (Pro-Pro-
Gly)10 is where the collagen peptide is known to exist in a triple helical state. 
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5.2.4 Surface roughness and surface energy  
The surface roughness measurements showed similar values for the respective groups i.e., 
uncoated and coated Mg-5Zr and Mg-5Zr-Ca alloys (Table 5.2). Increased surface roughness 
was seen in the coated alloys.  
 
 
 
 
Fig. 5.4 and Table 5.3 respectively shows the shapes of individual drops on the bare and 
coated alloys and left and right contact angles with the calculated surface energy values. The 
surface energies were calculated from the corresponding mean left and right contact angles 
and were in the range of 16-67 μJ/mm2. It is known that substrates with low surface energies 
are more hydrophobic than those with high surface energies [174]. The coated Mg-5Zr-Ca 
alloy showed the lowest average surface energy value of 18.99±1.97 μJ/mm2 making this 
alloy the most hydrophobic while the bare Mg-5Zr-Ca alloy without Col-I coating is the most 
hydrophilic.  
Alloy Ra Uncoated Ra Coated 
Mg-5Zr 0.129±0.00488 0.683±0.0157 
Mg-5Zr-Ca 0.146±0.00566 0.614±0.00672 
Table 5.2. Surface roughness of the bare and Col-I coated Mg-based alloy discs. Values were 
obtained from duplicate experiments using the alloy discs. 
Figure 5.3. Thickness of the coated collagen on the alloy surface, visualised by SEM. 
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Alloy Liquid Left CA Right CA 
Bare Mg-5Zr 
Water 25.25°r0.92 27.25°r0.49 
Glycerol 43.9°r1.27 46.65°r0.07 
Average SE 66.64r0.162  μJ/mm2 
Bare  
Mg-5Zr-Ca 
Water 23.3°r0.71 24.3°r0.99 
Glycerol 45.7°r0.57 48.1°r1.98 
Average SE 68.83r0.79  μJ/mm2 
Coated 
Mg-5Zr 
Water 81.25°±0.49 82.65°±0.21 
Glycerol 73.05°±0.64 70.30°±0.14 
Average SE 31.35°±0.14 μJ/mm2 
Coated 
Mg-5Zr-Ca 
Water 100.70°±4.67 100.95°±5.59 
Glycerol 96.65°±0.07 97.80°±1.98 
Average SE 18.99°±1.97 μJ/mm2 
Table 5.3. Individual surface energy of Col-I coated Mg-based alloys calculated from the 
respective left and right contact angles measured using water and glycerol. Contact angle 
measurement was done within 60 seconds after the liquid drop touched the alloy surface. 
Each alloy disc was used for measuring the contact angles for 3 times with 2 μL of liquid 
droplet on 3 different positions on the alloy surface, both with water and glycerol. 
Figure 5.4. Shapes of water and glycerol droplets used to estimate the contact angles of 
uncoated and Col-I coated Mg-based alloys.  The contact angles were recorded within 60 
seconds of the droplet touch on the alloy surface. 
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5.2.5 Surface morphology by SEM  
Fig. 5.5 (A-D) shows the surface morphology of uncoated and coated Mg-based alloy discs 
observed by SEM. Apart from irregular cracks and floral arrangements on the uncoated alloy 
surface there was no obvious difference in their morphology. The coated alloy surface 
showed presence of thin folds on their surface because of the dried layer of coated collagen.  
 
5.2.5 Cell viability 
The cell viability ratio (Fig. 5.5E) of MC3T3-E1 osteoblast cells after incubation for 12 h in 
the coated alloy extracts gave better results than those in the uncoated alloy extracts. It is 
evident from this point that Col-I coating made the alloy surfaces more compatible for 
osteoblast adhesion and viability.  
 
5.2.7 Histology and immunohistochemistry  
The ossification and secondary stabilisation around the Col-I coated Mg-based implants was 
checked by HE and TRAP staining. Fig. 5.6 (A, B, E and F) elucidates the implant-bone 
Figure 5.5. Scanning electron micrographs of the uncoated (Panels A and B) and Col-I coated 
(Panels C and D) Mg-based alloys. Panel E shows the cell viability of MC3T3-E1 osteoblasts 
on the uncoated and coated Mg-based alloys. ***p<0.001. 
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interface by HE staining, 1 and 3 months post-implantation. The coated Mg-5Zr alloy after 1 
month implantation showed a continuous fibrous layer around the implant area and a small 
layer of newly formed trabecular bone around it. After 12 weeks post-implantation, this 
fibrous layer becomes thinner and more amount of new bone can be seen in place of it. In 
coated Mg-5Zr-Ca implant, the formation of a rigid layer of new bone can be seen only after 
1 month implantation which indicates obvious ossification further leading to secondary 
stabilisation upon 3 months implantation. In Fig. 5.6 (C, D, G and H), the TRAP positive 
osteoclasts start becoming visible in the coated Mg-5Zr-Ca implant after 1 month 
implantation itself which becomes denser after 3 months. Higher number of osteoclasts in the 
vicinity of Mg-5Zr-Ca implant indicates better bone resorption and hence more appropriate 
bone remodeling around this implant. The degradation products are also visible as black 
residues which can be the reason for heightened osteoclast activation in the peri-implant area. 
The poor degradation of coated Mg-5Zr implant even after 12 weeks indicates its lesser 
osteoclast-inducing capacity. Fig. 5.7 shows mineralisation of the newly formed bones by 
MT staining and Col-I immunostaining, respectively. The unmineralised osteoid and the 
mineralised ECM were stained in red and blue, respectively, in MT staining of the bone 
tissue implants. The coated Mg-5Zr implant after 1 month showed some fibrous tissue and 
partially mineralised new bone trabeculae, distant from the implant area while a broader, 
more interconnected and fully mineralised bone close to the implant surface is visible for 
coated Mg-5Zr-Ca implant 1 month post-implantation. Since the mineral content of the 
woven bone is high, the 3 months implanted images indicate facilitation of rapid bone 
formation and mineralisation. 
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Figure 5.6. Images of bone sections stained with HE (Panels A, B, E and F) and TRAP 
(Panels C, D, G and H) after 1 month (Panels A-D) and 3 months (Panels E-H) implantation 
with coated Mg-5Zr and coated Mg-5Zr-Ca alloys. Note the rigidity of new bone in the 
coated Mg-5Zr-Ca implanted 1 month bone section indicating stronger and more mature bone 
formation within a short period of time. The coated Mg-5Zr-Ca alloy shows good expression 
of osteoclasts only after 1 month implantation (Panel D) which becomes denser after 3 
months implantation (Panel H) compared to the coated Mg-5Zr alloy. 
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Figure 5.7. Mineralisation of the newly formed bone shown by Masson’s Trichrome staining 
of bone sections after 1 month (Panels A and B) and 3 months (Panels E and F) implantation, 
and Collagen-I immunostained images of bone sections after 1 month (Panel C and D) and 3 
months (Panels G and H) implantation. Matured mineralised new bone could be seen for the 
coated Mg-5Zr-Ca alloy as compared to the coated Mg-5Zr alloy after 3 months 
implantation. In the Collagen stained images, the 3 months sections (Panels G and H) showed 
uniform arrangement of collagen stained osteoblasts which was seen to be haphazardly 
positioned in 1 month sections (Panels C and D). 
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The new bone mineralisation is supported by Col-I immunostaining, which shows dense Col-
I stained osteoblast lining around the implanted alloys. Even though Col-I positive osteoblast 
cells are uniformly distributed around both the coated alloys for 1 month implantation, its 
levels were higher in 3 months implanted coated Mg-5Zr-Ca implant. It can also be seen from 
Fig. 5.8 that the 3 months implanted coated alloys show a very dense and well-formed 
network of vimentin indicating the integrity of cytoplasm and cytoskeletal interactions in the 
ECM of the implanted alloys.  
 
The 3 months coated implant-B induced new bone shows the most uniformly arranged 
vimentin network clearly suggesting its role in better and stronger bone formation. The new 
bone formation by uncoated Mg-based implants has been shown in Fig. 5.9 and demonstrates 
very less new-bone formation. The surrounding fibrous layer of the implant area in HE 
staining indicated inflammatory response towards uncoated implants. The new bone matrix is 
seen in a distance away from the implant surface, giving rise to the phenomenon of distance 
Figure 5.8. Vimentin immunostained images of coated Mg-5Zr and coated Mg-5Zr-Ca alloys
implanted bone sections after 1 month (Panels a&b) and 3 months (Panels c&d) implantation. 
Noticeably uniform and dense vimentin network is seen for 3 months implanted sections. 
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osteogenesis. TRAP staining showed less number of osteoclast activation around the 
uncoated implants as compared to the Col-I coated implants indicating less amount of bone 
remodelling around the bare implants. MT staining showed very less new bone mineralisation 
of the uncoated Mg-5Zr-Ca implant, which becomes dramatically enhanced after Col-I 
coating as seen in Fig. 5.7.  
 
 
Figure 5.9. Histology images of uncoated Mg-5Zr and Mg-5Zr-Ca implanted bone sections 
after 3 months implantation. Panels A and B- HE staining, Panels C and D- TRAP staining 
and Panels E and F- Masson’s Trichrome staining. 
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5.2.8 BMC/BMD by DXA and blood cell count  
The quantitative in vivo new bone mineralisation was deduced from the mean BMC/BMD 
values of the implanted femur obtained by DXA radiography after 1 and 3 months 
implantation (Fig. 5.10). The BMC values showed higher mineral content for the coated 
alloys for both the implant periods. These values were highest for coated Mg-5Zr-Ca implant 
as compared to the control and coated Mg-5Zr implant. The BMC values were lowest for the 
uncoated Mg-5Zr-Ca implant upon 1 month implantation. However, there was no significant 
change for the BMD values of 3 months implanted alloys as compared to the control. This is 
possibly because the healed areas in these femur bones were much bigger than the healed 
areas of the control. 
 
 
Figure 5.10. DXA radiography detailing the BMC and BMD of the uncoated and Col-I
coated Mg-based alloys after 1 month and 3 months implantation. A significant raise in the 
BMC/BMD of 3 months implanted bone for coated Mg-5Zr-Ca implant directly suggests its 
enhanced osseointegration capacity giving rise to better bone content and density. 1M - 1
Month, 3M - 3 Months. *p<0.05, **p<0.01. 
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Table 5.4 lists the total blood-cell count of the rabbits performed before surgery, and after 1 
and 3 months of implantation giving information on inflammation and immune mechanism of 
the body. A significant increase in platelet (PLT) count was found for coated Mg-5Zr-Ca 
implant after 1 month. This could be probably due to higher platelet activation because of 
better bone induction and bone formation. The number comes down to normal level after 3 
months implantation period. Hence, this elevation does not indicate any kind of disturbances 
in the blood count.  
 
5.3 Discussion 
The surface characteristics and its influence on bone formation and mineral apposition is 
undeniably an important feature of the cell response. However, such data provide inadequate 
information regarding implant-host tissue interactions and their biological effects. To date, 
various strategies have been employed to improve this interaction by modifying the surface 
characteristics such as surface energy, roughness, topography and chemistry of the target 
alloys [179]. In the present study we have surface coated Ca-comprising Mg-5Zr alloys with 
Col-I and hypothesised that an enhancement in osteoinduction would lead to in vivo 
secondary stabilisation. Our results prove that coated Mg-5Zr-Ca implant demonstrate 
enhanced trabecular bone volume and mineralised bone matrix leading to implant secondary 
stabilisation. The elevations in surface roughness and hydrophobicity of the coated Mg-5Zr-
Ca implant may have played a role in this development. A major concern about using these 
implants resides in its tendency to react very fast in a physiological pH. The Mg-based 
implant surface undergoes a shielding outer layer of corrosion referred to as “passivation” 
[199].  
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Blood cells Before surgery 1 Month implantation 3 Months implantation Range 
  Control Mg-5Zr Mg-5Zr-Ca Control Mg-5Zr Mg-5Zr-Ca  
RBC (X106/uL) 6.44±0.43 5.85±0.72 6.37±1.21 6.41±0.49 6.87±0.37 6.82±0.64 6.75±0.22 5.3 - 6.8 
WBC (X103/uL) 6.87±1.32 13.26±2.35 9.33±2.03 7.91±3.37 8.10±0.57 9.22±1.01 11.82±4.08 5.1 - 9.7 
LYM% 85.12±8.13 63.05±25.38 83.08±2.29 69.21±6.58 58.75±2.05 87.13±4.76 82.97±1.65 39 - 68 
HGB (g/dL) 14.22±0.68 12.85±1.06 13.95±2.89 13.71±1.67 13.35±0.92 13.92±0.78 13.48±0.49 9.8 – 14.0 
HCT (%) 53.03±1.13 39.66±7.58 50.85±7.33 46.53±3.16 43.30±2.26 54.20±3.91 53.22±3.28 34 - 43 
MCV (fL) 82.65±7.28 67.53±4.66 80.15±3.70 72.60±0.71 63.15±0.07 80.00±2.26 78.85±2.24 60 - 69 
MCH (pg) 22.03±0.47 21.95±0.92 21.76±0.42 21.28±0.97 19.40±0.28 20.40±0.80 19.93±0.09 20 - 23 
PLT (X103/uL) 598.00±176 645.20±124 474.50±136 1271±135.76 204±22.63 345.83±85.56 391.17±244.89 158 - 650 
Table 5.4.  Blood cell count of the control and experimental animals implanted with Col-I coated Mg-5Zr and Mg-5Zr-Ca alloy implants. Cell 
count was performed before surgery and after 1 month and 3 months implantation period for the individual implanted alloys from the control and 
experimental animals. 
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When exposed to air, this phenomenon produces a magnesium oxide (MgO) layer that 
prevents the alloy surface from further reactions. However, this layer dissolves very fast in a 
physiological pH and hence the high chloride content of the host system causes corrosion on 
the implant surface. In our study, although Col-I coating imparted osteoinducing property to 
the alloy implants, the corrosion and degradation factors after coating remained 
underestimated. One aspect of Col-I coated alloy corrosion can be the presence of defects 
such as cracks, pits and vacancies inside the coating film, which enhances the corrosion rate 
[200], and might weaken the effect of coating. In our study, the degradation of a material 
happened because of its own solubility in the aqueous media and because of the reaction 
happening between the ions present in the media and the corrosion products of the material. 
Due to these activities, the in vitro degradation of the alloy is faster because of the 
availability of more aqueous media. However, the in vivo degradation is expected to be 
slower as there is less exposure of the implanted material to the aqueous media. During this 
period, the induction of new bone happens rapidly, which provides strength to the peri-
implant area, and the original strength of the degrading material becomes insignificant.  
 
5.3.1 Col-I coating and secondary stabilisation  
Our previous studies have demonstrated that uncoated Mg-5Zr-Ca alloys suppress bone 
turnover [171]. In the current study, the bone turnover, osseointegration and secondary 
stabilisation was achieved by twice its rate compared with the normal and uncoated Mg-
based implants. The histology results indicate direct new bone apposition with the implant 
surface and its mineralisation 3 months post-implantation after Col-I coating. Although there 
remains an intervening fibrous layer between the new bone matrix and the implant surface in 
1 month implanted alloy samples, it can be speculated that with time Col-I coating could help 
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in the surface fixation and secondary stabilisation of the Mg-5Zr-Ca alloy implant, which is 
clearly visible in 3 months implanted sections.  
The success of orthopaedic implants depends on implant stability, which can be divided into 
primary and secondary stability. The nature of the alloy decides the implant primary stability, 
which depends on the mechanical characteristics of the bone and the type of implant used 
[201]. They play a major role in the early events of endosseous healing and contribute to 
improved secondary stabilisation, which is achieved by contact osteogenesis [182]. It induces 
the formation of new bone through osteoconduction and gradual bone remodelling resulting 
in a stable new bone matrix at the bone-implant interface. This mechanism can be seen in our 
histology outcomes of 3 months implanted coated alloys, wherein the new bone formation 
can be seen in close proximity to the implant surface (Fig. 4E and 4F), which gradually 
progresses to mineral apposition (Fig. 5E and 5F). In contrast, the uncoated alloys 
demonstrate the mechanism of distance osteogenesis [171, 182], which causes stress 
shielding resulting in a number of critical clinical issues such as early implant loosening, 
damage of adjacent anatomical structures etc. [71].  
The role of Col-I in bringing this stabilisation to the coated alloys can be illustrated by its 
property of RGD peptide-cell interactions via integrin α2β1 [193]. Under appropriate 
circumstances, Col-I act as effector substance similar to a peptide hormone or cytokine that 
activates some of the differentiation-promoting activities associated with the ECM of 
osteoblast cells and stimulate their differentiation. Our data suggests fabrication of a well-
formed and rigid trabecular bone and its mineralisation in coated Mg-5Zr-Ca implant without 
any inflammation after 4-weeks of implantation, similar to the uncoated group after 12 weeks 
of implantation [171]. These results imply that it is the availability of a connecting factor for 
cells to dissolving Ca2+ ions, and not the Ca concentration, that contributes to osteoinduction. 
In our work, this role has been played by Col-I. It should, however, be emphasised that this 
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enhancement in new bone induction does not reflect any improvement in the mechanical 
characteristics of the implant material. Nonetheless, a significant difference in the physico-
chemical properties of coated alloys could be seen in our data. The elevated surface 
roughness and surface hydrophobicity of the alloy implants indicate induced adsorption of 
serum proteins upon contact with blood plasma. This mechanism can accelerate the formation 
of a stable bone-implant interface formed by reaction of the biologic cement-line matrix with 
the sensitive protein layer on the surface of the implanted area. This fact is supplemented by 
DXA of the experimental animals that gives us the BMC/BMD profiles of the implanted area 
for the quantitative bone growth and mineral accumulation on the implant surface. In our 
study, it is found to be highest in the coated Mg-5Zr-Ca implant in both 1 month and 3 
months implanted animals. This suggests better deposition of bone matrix on a pre-existing 
material surface and hence improved bone mineral density.  
 
5.3.2 Col-I coating and bone remodelling  
Osseointegration and implant stabilisation take place simultaneously with bone remodelling 
that occurs via a defined sequence of events [202] within the host bone and subsequently 
within the woven bone formed in the peri-implant interface. With time, this remodelling 
creates increased contact between the implant surface and the newly formed bone. This leads 
to formation of a mature cortical bone, which is the desired end result. Woven bone consists 
of loosely packed collagen fibers of varying size in a random spatial arrangement. Our data 
demonstrate woven bone formation in the form of trabecular bone (Fig. 4A and 4B) in 1 
month implanted animals which later progresses to cortical bone formation (Fig. 5E and 5F) 
in 3 months implanted animals. This study, along with the reports published earlier [203], 
suggest that over time, Col-I coated Mg-based alloys show remodelling and improved 
biological interlocking between implant and the host bone. Since more osteoclasts are 
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required for bone remodelling, it is not surprising from our data that the trabecular bone of 3 
months coated Mg-5Zr-Ca implant can remodel faster than the coated Mg-5Zr implant. This 
process of bone formation and resorption is coupled spatiotemporally and the required 
microscopic architecture for maintaining the mechanical properties of bone is preserved. 
Remodelling also depends on the preliminary biological processes of the implant area eg, 
blood coagulation, inflammation, and tissue formation. Platelets are the first cells to come in 
contact with the implant surface immediately after contact with blood [204]. Activation of 
platelets results into clot formation, which is necessary for the mechanical and biochemical 
components required for osteoconduction. The protein conformation of the host blood also 
determines the availability of the bioactive peptide sequences located within the protein for 
incoming cells [205].  
 
5.4 Summary 
The mechanical properties of Mg-5Zr and Mg-5Zr-Ca alloy implants are comparable to that 
of the natural bone; although Mg-5Zr-Ca alloy has a high corrosion rate in vitro, its 
performance as an implant material could be stabilised by surface coating with Col-I. Col-I 
coating enhances the surface energy and hydrophobicity of these alloys, and strongly 
influences the protein binding capacity onto the alloy surface leading to better osteoblast 
activity. Histology, immuno-histochemistry and radiology results suggest that Col-I coating 
enhances the rate of osseointegration with good level of new bone formation after only a 
month of implantation. It can be comprehended from our histology results that with time, 
Col-I coating helps in surface fixation and secondary stabilisation of the Mg-5Zr-Ca alloy 
implant. From our studies, we cannot absolutely determine whether the improved 
osseointegration, mineralisation and implant secondary stabilisation is solely due to Ca 
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content of the Mg alloys or due to the altered surface topography, but can however be 
comprehended due to the combined effects of Ca ions and Col-I coating. 
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Chapter 6 
Strontium Content and Collagen-I Coating Influence 
Osteogenesis and Bone Resorption 
 
6.1 Introduction 
Magnesium (Mg) alloys are attractive for several biomedical applications, ranging from 
dental prostheses [206] to cardiovascular implants [207]. They exhibit mechanical properties 
that are similar to human bone tissue such as similar material density and compressive 
strength [8]. In addition biocompatible Mg alloys are non-toxic and biodegradable – their in 
vivo biodegradation progressively stimulates their own activity and minimises their re-
accumulation and toxicity [8].  
The role of other metals in Mg alloys has been shown to influence their bone forming 
properties [6, 162, 166, 208]. Among other metals, the use of Sr in implants has become 
popular because strontium ranelate (SrR) has been approved for the treatment for 
osteoporosis, under the trade name of Protelos [209, 210]. Our earlier studies had 
demonstrated improved in vivo biocompatibility, osseointegration and bone remodelling by 
modulating the contents of Sr and Zr in Mg-Zr-Sr implants [171, 211]. Other studies have 
also indicated the role of Sr content in implants for better bone formation [212, 213], 
improved bone resorption [214, 215] higher bone collagen synthesis [212], more precipitation 
of hydroxyapatite [216, 217] and increased hardness of trabecular and cortical bones [218]. 
Sr has been shown to have some negative effects on bone formation also such as defective or 
abnormal mineralisation of the bone matrix [219-221], hence the use of Sr in bone implants 
needs to be re-evaluated. The use of implants with bioactive coatings, such as RGD peptides 
or Collagen Type-I (Col-I), also stimulates osteoinduction [222]. These coatings enhance the 
interaction between the implant surface and extracellular matrix (ECM) at the implant site 
Chapter 6. Strontium Content and Collagen-I Coating Influence Osteogenesis and Bone 
Resorption 
 
97 
 
thereby increasing mineralisation of the pre-existing bone and making it more rigid and load-
bearing. 
In this study we have analysed the in vitro and in vivo properties of Col-I coated Mg-Zr 
alloys containing high (5wt%) or low (2wt%) quantities of Sr. We have evaluated the dose 
and time-dependent influence of Sr quantity and Col-I coating of the implants. Our 
investigation indicated that Sr content of implants influenced bone specific gene expression 
in vitro and implant-bone apposition during in vivo bone formation; Col-I coating of implants 
enhanced the in vivo mineral deposition in newly formed and pre-existing bones. 
 
6.2 Results 
6.2.1 Cell viability, cell adhesion and mineralisation 
The MC3T3-E1 osteoblasts showed good compatibility and viability with the Col-I coated 
Mg-Zr-Sr alloys. Fig. 6.1 shows the cell viability ratio with the uncoated and coated alloy 
extracts.  
 
Figure 6.1. Cell viability ratio of MC3T3-E1 osteoblasts cultured with alloy extracts of bare 
and Col-I coated Mg-Zr-Sr alloys and incubated for 24 hours. *p<0.05, **<p<0.01, 
***p<0.001. 
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Fig. 6.2 depicts the SEM images of morphology and mineralisation of osteoblasts on the 
uncoated and coated alloy surfaces. The osteoblasts exhibited cell death after incubation for 
24 h on the uncoated surface of no-Sr alloy. However, after coating the alloys with Col-I and 
when cultured under similar conditions, better cell adhesion demonstrating extensive network 
and mineral deposition was observed.  
 
6.2.2 In vitro Expression of bone markers 
The comparative gene expression profiles of bone related markers in osteoblasts, after their 
growth for 1 or 7 days in different uncoated alloy extracts were measured by RT-PCR (Fig. 
6.3). Expression of all genes was clearly detectable in cells after 7 days of growth in all alloy 
extracts, however, it was higher in cells grown in extracts of Mg-2Zr-5Sr as compared to 
those grown in extracts of Mg-Zr-2Sr. This indicated that higher Sr containing alloys had 
better gene inducing ability directed towards bone differentiation. Interestingly BMP-2 gene 
expression was detectable at 24 h and 7 days but its levels were not significantly different 
among the alloys at both time points.  
Figure 6.2. Morphology of MC3T3-E1 osteoblasts on bare and coated Mg-Zr- based alloy 
surfaces after 24 h of incubation. 
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Figure 6.3. The expression of genes related to bone specific markers, proteins related to bone 
ECM and proteins of non-collagenous bone matrix after 24 h (1d) and 7 days (7d) of
incubation in the respective coated-alloy extracts. *p<0.05, **p<0.01. 
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6.2.3 In vivo bone inducing activity  
Fig. 6.4 shows HE stained images of the newly formed bone around the Mg implants, after 1 
and 3 months implantation. In the coated implants, initiation of bone formation could be seen  
 
 
early after 1 month implantation (Panels A-C), which gives rise to mature and fully 
developed trabecular bone after 3 months (Panels D-F). Very little or no discontinuity 
between the cement line matrix and the newly formed bone could be seen for coated Sr-
containing implants, whereas a large gap could be seen for coated no-Sr implant. The 
Figure 6.4. Hematoxylin and Eosin staining of bone sections implanted with Col-I coated and
uncoated Mg-Zr-based alloys after 1 month and 3 months post-implantation. Panels A-C:
Col-I coated 1 month study, Panels D-F: Col-I coated 3 months study, Panels G-I: Uncoated 3
months study. 
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uncoated alloys also showed good amount of bone formation by Sr-containing implants, after 
3 months implantation (Panels G-H). 
The TRAP-positive cells were minimal in the sections of coated implants (Fig. 6.5, panels A-
F). However, the number of TRAP stained cells was seen to be higher in the bone sections of  
 
uncoated implants, especially for high-Sr alloy, suggesting excessive bone turnover (Fig. 6.5, 
panel I). This difference in staining, between the alloys containing low and high-Sr and 
between the uncoated and coated implants, indicates the role of Sr concentration and Col-I 
coating in bone induction and turnover by Mg-Zr-Sr alloys.  
 
Figure 6.5. TRAP staining of osteoclasts for bone sections implanted with Col-I coated and
uncoated Mg-Zr-based alloys after 1 month and 3 months implantation. Panels A-C: Col-I
coated 1 month study, Panels D-F: Col-I coated 3 months study, Panels G-I: Uncoated 3
months study. 
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6.2.4 Implant induced bone mineralisation  
Fig. 6.6 shows Masson’s Trichrome staining, demonstrating coated (panels A-F) and 
uncoated (panels G-I) peri-implants. Homogeneous mineral deposition on the new bone could 
be seen in all the implant types, with superior bone mineral in coated high-Sr implant, after 
both 1 month and 3 months (panels C & F). 
 
 
Interrupted and heterogeneous bone mineral deposition was seen by the uncoated implants 3 
months post-surgery (Panels G-I). Irrespective of the Sr concentration in uncoated alloys, 
bone mineralisation could be seen in all the implant types. However, the time- and coating-
dependent bone mineral deposition by the coated implants could have been influenced due to 
Figure 6.6. Masson’s Trichrome staining of bone sections implanted with Col-I coated and
uncoated Mg-Zr-based alloys 1 month and 3 months post-implantation. Panels A-C: Col-I
coated 1 month study, Panels D-F: Col-I coated 3 months study, Panels G-I: Uncoated 3
months study. The blue stain indicates collagen matrix of mineralised bone. 
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controlled release of Sr ions by Col-I coating in the vicinity of the implant area. This result 
matches the Alizarin Red staining of coated implants (Fig. 6.7) in which the coated low-Sr 
 
implant showed partial Alizarin Red staining for the same 3 months period of implantation, 
whereas coated no-Sr implant displayed very little staining. The Ca content of newly formed 
bone indicates its extent of maturity, and the bone response observed in the sections of coated 
implants suggests the influence of Sr content in bone formation and its degree of 
calcification. 
 
6.2.5 Bone density and mineral concentration  
The BMC and BMD of the implant sites give us an idea about bone healing from the mineral 
content and density of the newly formed bone. As seen in Fig. 6.8, there is a significant 
increase of BMC and BMD in the coated high-Sr implant site, compared with the uncoated 
and coated alloys having no Sr or lower concentration of Sr, in both the implant periods (1 
Figure 6.7. Alizarin Red staining of bone sections implanted with Col-I coated Mg-Zr-based
alloys after 1 month and 3 months implantation. Panels A-C: Col-I coated 1 month study, 
Panels D-F: Col-I coated 3 months study. The red stain indicates accumulation of calcium in
mineralised bone. 
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month and 3 months). These results agree with our histology data, which confirms that Col-I 
coated high-Sr implant is superior to other uncoated and coated alloys in enhancing bone 
mineral formation in rabbit femur. 
 
6.3 Discussion 
There has been significant progress in the development of biodegradable alloys that exhibit 
good biocompatibility and osteoinducing properties [223, 224]. Mg based alloys have proven 
to be useful in this direction because of their properties mentioned above (see references in 
Introduction). However, further optimisation of their constitution and modifications of their 
surface characteristics are necessary to make them biologically and physico-chemically more 
suitable for medical applications. Extending upon some of our earlier results on Mg based 
alloys [171, 181, 211], we have enumerated the role of Sr concentration and Col-I coating in 
Mg-Zr-Sr alloys with reference to their in vitro and in vivo bone inducing potential. 
Figure 6.8. Quantitative in vivo mineralisation of the peri-implant area by evaluation of femur 
BMC and BMD of experimental animals implanted with Col-I coated- Mg-Zr-based alloys 
after 1 month and 3 months implantation. *p<0.05. 
Chapter 6. Strontium Content and Collagen-I Coating Influence Osteogenesis and Bone 
Resorption 
 
105 
 
6.3.1 Sr concentration and Col-I coating enhance osteogenesis 
Our results in Fig. 6.1 and Fig. 6.2 showed that high Sr concentration in Mg-based alloys is 
associated with superior viability and proliferation of osteoblasts on their surfaces. These 
alloys also induced higher expression of genes related to bone markers (Fig. 6.3). The level of 
bone formation and its maturation was found to be affected by time up to three months, as 
seen from the histology and DXA results (Figs. 6.4-6.8). Since the collagenous matrix of 
newly formed bone is depicted by Masson’s Trichrome staining, our results indicate that 
increased Sr concentration in Mg alloys influences the collagenous matrix formation by 
osteoblasts, without inducing any negative effects in long-term matrix mineralisation, as also 
stated by Barbara et al. (2004) [225]. These results are also consistent with previous studies 
showing that Sr increases trabecular bone formation in vivo in rats, mice and humans [226]. 
From the histology results, no defects in bone apposition and calcification were observed. 
This homogeneity could be because all the existing bone around the peri-implant area 
consisted of new bones, formed during the period of implantation. Also, there is a decreased 
expression of osteoclast markers in the bone sections of high-Sr-containing implants, 
indicating the inhibitory effect brought upon by Sr concentration on osteoclast resorption, 
without any cytotoxic effects. Although the precise mechanism of the role of Sr concentration 
on osteogenesis and bone turnover is not fully understood, the increased bone formation and 
its suppressed turnover, within the specified implant period, suggest that Sr is dose 
dependently taken up and distributed by the osteoblasts in newly formed bone tissue.  
 
6.3.2 Role of Sr concentration in bone formation and resorption 
The Sr ions released from the degrading implant possibly affects the osteocytes, which in turn 
controls the activity of osteoblasts and osteoclasts [227]. The mechanical pressure applied by 
the newly forming bone matrix is sensed by osteocytes. Less activity in the surrounding peri-
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implant area activates the osteoclasts for bone resorption or inhibits the osteoblasts for bone 
formation. These phenomena are the response to mechanical stimuli, and any factor that 
affects these stimuli can affect bone formation and/or resorption. Sr can replace these 
mechanical stimuli, as osteocytes devoid of any external stimuli enhance the osteoclast bone 
resorption in vivo, as seen in our uncoated Sr-containing implant sections and reported by 
others [228, 229]. Considering the site of bone resorption and the position of osteoclasts, the 
applied pressure signals the osteoclasts to reduce their activity in the presence of certain 
concentration of Sr, which in our study has been shown to be 5 wt%. The activated osteocytes 
also produce osteoblast-stimulating factors, including BMP-2, for bone formation. Also, the 
action of Sr on bone resorption can be associated with a Ca-like effect on bone, wherein high 
concentrations of Ca have been shown to inhibit osteoclast activity in vitro [230] and in vivo 
[231]. 
 
6.3.3 Role of Col-I in enhanced bone formation  
The enhanced osteogenesis can also be associated to Col-I coating. Availability of coating on 
the Mg alloy surface leads to gradual release of degrading Sr ions upon implantation. The 
slow release of ions not only promotes osteoblast proliferation, but also facilitates the 
precipitation of apatite, thus increasing the mechanical strength of the bone-implant interface 
[216, 217]. Consistent with this interpretation, Barbara et al. (2004) [225] also found that Sr 
uptake is directly proportional to Mg uptake and free Mg ions act as stimulators of osteoblast 
activity [171]. In our study, the gradual release of Sr ions due to Col-I coating creates 
availability of free Mg ions for longer periods throughout the implantation. This could have 
contributed to superior osteoblast activity and a subsequent increase in ECM quantity in the 
Sr-containing peri-implant bone area. Hence, Col-I acts as a connecting factor between the 
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alloy surface and the extent of availability of degrading ions to the peri-implant area required 
for bone ECM quality and quantity. 
 
6.3.4 BMC/BMD and bone mineralisation  
Our findings, along with the previous report [171], raise the possibility that high Sr content (5 
wt%) in Mg alloys may have beneficial effects on osteogenesis, with decreased bone 
resorption, while maintaining enhanced new bone mineralisation, when coated with Col-I. 
However, it affects not only the process of new bone formation but also the bone mineral 
deposition, as seen from the histology and BMC/BMD results of DXA radiography in our 
study. However, further studies need to be carried out to understand the precise impact of Sr 
concentration on bone mineralisation. It would be valuable to conduct future work to estimate 
the precise amount of new bone that is formed around the implant. Measuring the deposition 
of Sr ions in the newly formed bone will provide us with a more accurate knowledge of Sr 
incorporation in the implant site from biodegrading Mg implants. Gene expression for 
osteoblasts grown in coated-alloy extracts was not quantified due to the potential effect of 
coated Col-I in the growth of cells. Nonetheless, our study helps in understanding the basic 
optimum elemental constituents required in Mg alloys for their application as orthopaedic 
implants. 
 
6.4 Summary 
Our work provides experimental evidence that Mg-based alloys containing high-Sr (5 wt%) 
and coated with Col-I, enhances the rate of osteogenesis and reduces bone resorption over 
short term implantation, resulting in increased bone mass. This gives rise to increased 
trabecular bone volume without altering mineralisation process of the newly formed bone. 
Such alloys can help in the prevention of bone loss and increase bone mass and maturity. 
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This work confirms that prolonged exposure of Sr to the implant site results in better bone 
formation and lower bone turnover, without any deleterious effects of long-term Sr exposure 
on bone mineralisation. We also confirm the effect of Col-I coated high-Sr containing Mg-
based alloys in bone resorption, by altering the in vivo osteoclast properties. Our data 
describe a positive effect of Col-I coated high-Sr containing Mg alloy (Mg-2Zr-5Sr) on 
osteoblasts and mineral deposition and negative effect on osteoclasts and bone resorption.  
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Chapter 7 
General Discussion 
 
7.1 Highlights of Research 
The potential advantages of Mg-based materials over other non-resorbable biomaterials, 
especially for orthopaedic applications, are obvious. However, in spite of significant research, 
there remain challenges with the successful implementation of Mg-based materials in a 
variety of dental and orthopaedics applications. Many of these challenges are related to 
corrosion and early degradation. This chapter discusses the highlights of this work in favour 
of Mg biomaterials, in the context of alloying, surface modification and osseointegration, as 
implant material in orthopaedics.  
 
7.1.1 Impact of Mg alloying elements in bone formation and osseointegration: the 
requirement to alloy Mg- strength versus toxicity 
Pure Mg does not provide the necessary mechanical and corrosion properties for implant 
applications. Therefore, potential alloying elements need to be carefully considered. Of all 
the available alloying elements to date including Al, Zn, RE, Li, and Mn, we chose to alloy 
Mg with Zr, Ca and Sr because of the advantages described in chapters 4, 5 and 6. Since our 
studies were typically short-term, the results may have been influenced directly or indirectly 
by corrosion of the alloy itself, especially in in vitro tests. In such cases, it is practically 
impossible to isolate the effect an increased corrosion rate might have had on the perceived 
toxicity of the investigated alloy. While still providing the requisite mechanical properties, 
these alloying elements can provide mechanical or corrosion benefits when alloyed with Mg. 
Sr proved to be the most biocompatible Mg-alloying element, although studies using other 
concentrations of Sr should continue (especially over long-term usage) before they can be 
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developed fully. This has been suggested by the formation of the Mg17Sr2 intermediate phase 
in Sr containing Mg based alloys, which improves their corrosion resistance. In our study, Ca 
or only Zr containing Mg alloys were unstable and upon degradation in vivo, they showed a 
lot of residual alloy material at the implant site. This could also lead to a preliminary 
conclusion that formation of the Mg17Sr2 intermediate phase gives in vivo stability to the 
alloys and leads to osseointegration of Mg-Zr-Sr implants.  
 
7.1.2 Impact of Col-I coating on osseointegration and implant stability 
An area that has recently received wide attention in the field of Mg biomaterials is the study 
of surface modification methods to minimise their degradation rates. For coating of 
biodegradable Mg alloys, the appropriate criterion is that they are biocompatible and fully 
degradable. This becomes important for understanding what occurs to the implant material 
itself over the implant life cycle. In the case of biodegradable materials like Mg-based alloys, 
coating cannot be a solution to corrosion as the alloy itself has to be accessible to the 
surrounding bone tissue for new bone formation and its regeneration. Ideally, the coating 
should itself degrade gradually, helping to control the overall corrosion process while leaving 
no harmful traces. The Mg alloys used in this study has been functionalised with Col-I 
protein for assisting in bio-acceptance of these alloys, if not to improve the corrosion 
properties. Being a biomolecule, Col-I does not play an important role in preventing 
corrosion of Mg-based alloys; however it could enhance the osseointegration and stability of 
the implanted alloys for a longer period, until complete healing of the bone is observed. 
Interestingly, it could increase the proximity of new bone formation to the implant surface for 
Ca-containing Mg alloys (Chapter 5), affecting the secondary stabilisation of implanted 
alloys and stimulating mineral deposition in Sr-containing Mg-based alloys (Chapter 6).        
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7.2 Work Required to Connect the Gaps 
While effective designing of materials is the standard criteria in engineered bone substitutes, 
it is also of utmost importance for a clinically relevant device to integrate biologically during 
its existence with the host tissue. This section summarises the points that connect the gaps 
between defining the precise role of Mg-based alloys in bone tissue-engineered alternatives 
and other available materials used in bone grafting techniques and recent advances in 
biomaterials research.  
 
7.2.1 Live cell imaging for studying the cellular dynamics to degrading alloys 
To understand the influence of degrading alloys on cellular behaviour, the cellular dynamics 
(size, polarity, movement) and nuclear dynamics  (size, circularity, movement) and the 
temporal changes in these two aspects of the cells need to be studied. This can be done by 
tagging the focal adhesion complexes of the cells with fluorescent proteins and use as 
markers for quantitative analysis of the adhesion sites and rates following time-lapse 
experiments.  
 
7.2.2 Measurement of in vivo corrosion or biodegradation rate 
There are many in vitro corrosion measurement methods described in the literature, including 
quantification of pH values, Mg ion release, hydrogen evolution, mass or volume changes, 
and potentiodynamic polarisation [232]. Several reports have included measurement of Mg 
degradation in commonly used inorganic media with their inorganic ingredients similar to 
those of plasma [233], such as phosphate buffer solution (PBS), hanks balanced salt solution 
(HBSS), and simulated body fluid (SBF) and cell culture media (e.g., DMEM) [234]. 
However, the difference between the environments under in vitro and in vivo conditions 
suggest probable difference in the degradation behaviour of the alloys, owing to higher 
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deposition of ions in the vicinity of the degrading alloy under in vitro conditions. Due to this, 
measurement of the degradation rate under in vivo conditions, after the alloy has been 
implanted into the host tissue, becomes necessary. Micro-computed tomography (μCT) 
analysis is a necessary criterion in this aspect as an established monitoring protocol to 
compare the volume changes of the implanted alloys to assess their corrosion rates in vivo. It 
is appropriate to compare the densities of implants while they are still inside the host tissue, 
as the corroded portion has lower substrate density than its residual part. pH measurement is 
also a user-friendly and a quick qualitative assessment that can be applied for monitoring the 
corrosion rates through the determination of OH– concentration in the extracts, urine being 
the target extract under in vivo conditions, as the dissolution of Mg is accompanied by the 
release and precipitation of OH–. 
 
7.2.3 Measurement of bone bonding strength  
Bone bonding is an important feature that describes the strength of the newly formed bone on 
the cement line matrix. The understanding of bone bonding can be elucidated from the 
resorption surface created by osteoclasts at the BRC (Fig 2.8) and the initial matrix synthesis, 
which occurs during the de novo bone formation. This can be achieved by focusing on the 
structure of the resorbed bone surface and the cement line-ECM that occupies the interface 
between new bone and old bone during the process of bone remodelling. 
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Chapter 8 
Conclusions and Recommendations for Future Work 
 
8.1 Conclusions 
Mg alloys as biodegradable implants are promising replacements for currently available 
implant materials and have become popular due to advancements in technology, allowing 
improved control of corrosion. Although this has led to success in vascular applications, 
some of the most important considerations regarding biological responses are required to 
ensure the continual and effective development of Mg based biomaterials for clinical 
purposes. In many cases, it is realistically impossible to determine the effect an increased 
corrosion rate might have on the perceived toxicity of the investigated alloy. This thesis 
addresses the biological and cellular properties imparted by Mg-based alloys upon 
implantation into a rabbit model, and investigates the role of Mg and its alloying elements in 
cellular behaviour and their response. In summary, the following conclusions can be drawn 
from this thesis:   
 
1. Effect of zirconium, calcium and strontium contents on implant-induced 
osseointegration 
All four alloys, namely Mg-5Zr, Mg-5Zr-Ca, Mg-2Zr-5Sr and Mg-Zr-2Sr, demonstrated 
mechanical properties close to natural bone. Notable differences in contact angles and 
calculated surface free energies were seen for all alloy surfaces, Mg-Zr-2Sr being the most 
hydrophobic and having the lowest surface energy. The inclusion of Sr gives Mg-Zr implants 
the property of contact osteogenesis. The addition of Sr also notably increases early bone 
apposition in rabbit cancellous bones. The optimum concentration for the best 
osseointegration of Sr for Mg-Zr-Sr alloys has been found to be 2wt%. The influence in the 
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rate and extent of osseointegration is probably due to the physico-chemical changes brought 
about by the change in surface energy of Sr-containing Mg-Zr alloys. Hence, Zr and Sr have 
a positive impact on the mechanical and biological properties of Mg-Zr-Sr alloys. Ca has a 
negative impact on osseointegration because of its rapid corrosion property. The surface 
topography of Mg-Zr-Sr alloys is compatible as in vivo implants and these materials can 
generate new bone when used as bio-implants. It also helps in complete degradation of the 
implant within the specified period of surgery 
 
2. Collagen type-I leads to in vivo matrix mineralisation and secondary stabilisation 
Col-I coating of Ca-containing Mg-Zr based alloys enhances their in vivo biocompatibility 
and osteogenesis capacity. The mechanical properties of Mg-5Zr and Mg-5Zr-Ca alloy 
implants are comparable to that of natural bone, as demonstrated from their phase 
constituents, microstructure and compressive strengths. The negative impact of Mg-5Zr-Ca 
on osseointegration and implant stability could be improved by surface coating with Col-I, 
which helps in surface fixation and secondary stabilisation. Col-I coating enhances the 
surface energy and surface hydrophobicity of these alloys and strongly influences the protein 
binding capacity onto the alloy surface, leading to better osteoblast activity. Col-I coating 
enhances the rate of osseointegration with good levels of new bone formation after only a 
month of implantation, as demonstrated by histology, immuno-histochemistry and radiology. 
Our results provide new information on the quality of bone mineralisation and suggest an 
earlier onset of bone remodelling process compared with the uncoated counterpart alloys.  
 
3. Strontium content and collagen-I coating influence osteogenesis and bone resorption 
 For developing new Sr-containing Mg-Zr based biodegradable implants with high 
osteogenesis and mineralisation properties, the Sr levels should be ≥5 %. Our results confirm 
Chapter 8. Conclusions and Recommendations for Future Work 
 
115 
 
that Mg-based alloys containing high Sr content, which in our study is 5wt%, and coated with 
Col-I reduces bone resorption and increases bone formation and osteogenesis during shorter 
periods of time. Lower yet prolonged exposure of Sr to the implant site, by having high 
concentration of Sr and surface coating with Col-I, has helped in better bone formation and 
lower bone turnover. This enhancement in bone formation is followed by the absence of any 
negative effect of long-term exposure of the degrading particles on bone mineralisation. Such 
alloys can help in prevention of bone loss and increase in bone mass and bone strength. We 
also confirm the effect of Col-I coated Mg-2Zr-5Sr alloy in bone remodelling by altering the 
in vivo osteoclast properties. Further, the enhanced osteogenesis due to Col-I coating affects 
primarily the initial stages of bone healing.  This can indicate decreased susceptibility for 
infections and earlier initiation of wound recovery.   
 
8.2 Recommendations for Future Work 
One of the most demanding challenges towards systemic development of future Mg 
biomaterial is related to the fact that a strong knowledge of material science, corrosion 
engineering, and biological interactions is required to fully understand the underlying 
biology. The following directions can be looked into for future focus in Mg biomaterials. 
 
1. The in vitro tests are done in closed conditions and are devoid of dynamic environment 
like the human body. As a result, the conditions alter rapidly due to which many processes 
are affected, including corrosion, pH changes, the degrading metal ion concentration, 
solubility of the corroding products and hydrogen gas evolution. Consequently, there is a vast 
difference between the in vitro and in vivo results. To make a more realistic conclusion from 
our studies, prolonged in vitro tests should be performed under conditions that can mimic 
physiological conditions and which can be compared in parallel with the in vivo studies.     
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2. The reliability of long-term in vitro and in vivo studies in terms of basic aspects, such as 
toxicity imparted by the degrading alloying elements, has to be addressed to date. Without 
this information it may be premature and unethical to conclude any kind of short term as well 
as long term in vivo studies related to biological and cellular response. 
 
3. The long-term in vivo study of the degradation and wear resistance of metals can be 
associated with pseudo-tumours. The formation of pseudo-tumours can be seen as soft-tissue 
masses relating to post-surgery effect due to the elevated levels of metal ions in serum, 
especially when the implanted alloys have minimal wear-resistance, as in the case of Mg 
alloys. Although excessive accumulation of Mg ions in the body is almost impossible as they 
are excreted out from the body, the degradation of the alloys may lead to accumulation of 
other elements that have been used as alloying agents to strengthen the corrosion resistance of 
Mg alloys. Pseudo-tumours may involve a cytotoxic response and a delayed hypersensitivity 
response to the degrading alloy particles. A long term study of the implants in higher animals 
that are more phylogenetically related to humans would give us a better idea of the tumour 
response of host tissue to the degrading alloy particles.  
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